Beta-cell β1 Integrin Deficiency During Second Transition Stage Of Fetal Pancreas Development On Islet Growth by Win, Phyo
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
8-8-2018 9:30 AM 
Beta-cell β1 Integrin Deficiency During Second Transition Stage 
Of Fetal Pancreas Development On Islet Growth 
Phyo Win 
The University of Western Ontario 
Supervisor 
Wang, Rennian 
The University of Western Ontario 
Graduate Program in Physiology and Pharmacology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Phyo Win 2018 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Cellular and Molecular Physiology Commons, and the Endocrinology Commons 
Recommended Citation 
Win, Phyo, "Beta-cell β1 Integrin Deficiency During Second Transition Stage Of Fetal Pancreas 
Development On Islet Growth" (2018). Electronic Thesis and Dissertation Repository. 5627. 
https://ir.lib.uwo.ca/etd/5627 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
i 
 
Abstract 
β1 integrin has been shown to be important for pancreatic beta-cell growth and functioning. 
Congenital and postnatal studies have shown beta-cell mass reduction with β1 integrin 
knockout (β1KO). Using an inducible cre recombinase (CreERT) expressed from the mouse 
insulin promoter (MIP) crossed to a line in which Itgb1 (β1 integrin encoding gene) was 
flanked by loxP sites (MIP-CreERT+; β1itg designated as MIPβ1KO), we examined the in 
vivo temporal role of beta-cell β1 integrin effect on islet growth during the second transition 
stage of pancreas development.   
Prenatal MIPβ1KO mice displayed decreased beta-cell area, mass, density and proliferation. 
In addition, a decrease in phosphorylated-ERK activity, islet vascularization and nascent 
endocrine cells in the ductal region was observed. However, normal levels of transcription 
factors needed for beta-cell development was seen. This study may suggest that β1 integrin 
plays an important role in prenatal beta-cell development during the second transition stage. 
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Chapter 1 - Introduction 
1.1 Significance 
The development of the pancreatic and islet of Langerhans requires highly 
controlled regulation of transcription factors and signaling pathways necessary for 
endocrine cell differentiation, migration, proliferation, and maturation. The interaction 
between islet cells and the extracellular matrix through the integrin family is required for 
islet beta-cell survival and function. Integrins are also an important factor during the 
development of fetal islet cells. To date, the β1 integrin subunit has been shown to affect 
islet morphology and function in postnatal murine pancreas. However, the temporal 
significance of beta-cell β1 integrin during the second transition stage of pancreas 
development has yet to be investigated. This thesis examines the role of β1 integrin 
during in utero development of the differentiated beta-cell population. The findings from 
this study will improve our understanding of the effects of β1 integrin activity on 
developing beta-cells during the second transition stage of embryonic pancreas growth, 
which may lead to potential susceptibility towards diabetes postnatally.  
1.2 The Pancreas  
The pancreas is a glandular organ that consists of a head, neck, body, and tail 
region, and is located posterior to the stomach in mice (Gittes, 2009). The pancreas 
contributes to both the digestive function and regulation of blood glucose through the 
exocrine and endocrine compartments, respectively. The exocrine acinar cells and ductal 
system, which secrete digestive enzymes and bicarbonate, respectively, to the duodenum 
through the pancreatic duct, make up 97% of total murine pancreatic tissue. Scattered 
between the acinar lobules are endocrine cell clusters referred to as the islets of 
Langerhans, which contribute to 2-3% of the pancreatic compartment. Murine islets are 
primarily made up of a dense core of insulin-secreting beta-cells (β) (~80%) and 
glucagon -releasing alpha-cells (a) (~10%) along the islet’s periphery. The other 
endocrine cells of the islets are delta (d), epsilon (e), and pancreatic polypeptide (g), 
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which releases somatostatin, ghrelin, and pancreatic polypeptide, respectively. The alpha 
and beta-cells of the endocrine system work in an antagonistic manner to regulate blood 
glucose homeostasis. In response to low glucose levels, glucagon promotes elevated 
glycogenolysis from the liver and causes an increase in the circulating glucose level. 
Conversely, when glucose levels are high, insulin is released to stimulate insulin 
receptor–induced glucose uptake in the skeletal muscle and adipose tissue and promotes 
glycogenesis in the liver. To ensure the development of functional glucose-regulating 
beta-cells, the embryonic pancreas requires tightly regulated temporal expression of 
transcription factors (TF).  
1.3 Development of the Murine Pancreas  
Murine pancreatic development is divided into the first (embryonic day (e) 8.5-
12.5), second (e12.5-19.5), and third (e19.5-postnatal day (p) 21) transition stages. Each 
transition stage requires the timed expression of specific TFs to ensure the proper cell 
commitment and maturation of the functional pancreas (Figure 1.1). The detailed 
processes of pancreas development are outlined below and includes a brief description of 
the major changes to morphology and TF expression in beta-cell development.  
1.3.1 Morphological Changes in Pancreatic Development  
The region of the foregut endoderm that forms the pancreatic anlage becomes 
prominent at e8.5 with evagination of the ventral and dorsal epithelial buds into the 
surrounding mesenchyme (Zorn & Wells, 2009). By e10.5, the undifferentiated 
pancreatic epithelium is mainly surrounded by mesenchymal tissue and the dorsal 
pancreatic bud extends to produce a neck connected to the primitive gut via the central 
lumen (Jørgensen et al., 2007). The pancreatic buds at this stage is composed of a 
multilayered core with non-polarized pancreatic progenitor cells located throughout the 
bed of nascent cells. Shortly after e10.5, the progenitor cells gain apical-basal polarity 
and form microlumens (Kesavan et al., 2009). Around e11.5, the primitive gut tube 
rotates and fuses the ventral and dorsal buds, forming one pancreatic organ with an 
interconnected luminal plexus by e12.5 (Kesavan et al., 2009; Pan & Wright, 2011; 
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Villasenor et al., 2010). High levels of cell proliferation also take place during the 
formation of this primitive branched tubular structure (Gu et al., 2002; Pictet et al., 1972). 
The initial formation of the bud-like microlumen and blood vessels within the ductal 
region are also observed at this stage (Magenheim et al., 2011; Pierreux et al., 2010). 
Pancreas tubulogenesis begins at the start of the second transition stage (e12.5), 
with the apical cell membrane facing the central lumen and the basal cell layer 
associating with the extracellular matrix (ECM) (Villasenor et al., 2010). The newly 
formed monolayer extensively branches and expands to form a complex network of 
tubules from e12.5 until birth (Gittes, 2009). During the branching process, cells located 
at the tip of the epithelia tubule form the acinar-committed lobules through adjacent ECM 
integrin signaling (Shih et al.,  2016). Endocrine precursor cells also differentiate and 
migrate from the ductal epithelial cells towards surrounding islet clusters during this 
period. This process of endocrine cell neogenesis is observed throughout the second and 
third transition stages until p21 (Scaglia et al., 1997). By e14.5, the extensive pancreatic 
plexus has remodeled toward a single lumen (pancreatic duct) to support unidirectional 
tubule flow towards the duodenum (Villasenor et al., 2010). By the end of the second 
transition stage, the pancreas had been organized into defined exocrine and endocrine 
compartments.  
The third transition stage of murine pancreas development involves the 
remodeling of a structurally organized pancreas. Most of the exocrine cells are 
aggregated near the ductal network with the islets distributed throughout the pancreas 
(Pictet et al., 1972). Development from e19 to p21 results in a gradual decrease of beta-
cell neogenesis from the ductal epithelium and the replication of pre-existing cells 
becomes responsible for formation of new beta-cells (Dor et al., 2004). This remodeling 
stage ensures the robust formation of beta-cells with the ability to manage glucose 
homeostasis in the mature pancreas (Hill, 2005).  
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Figure 1.1: A schematic of important time points during islet development in mice.  
Mouse pancreatic development is divided into the first (e8.5-e12.5), second (e12.5-
e19.5), and third (e19.5-p21) transition stage. Beta-cell neogenesis occurs throughout 
prenatal and neonatal pancreas development, but declines after the neonatal period with 
replication becoming the main source of postnatal beta-cell growth.  
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1.3.2 Transcription Factors in Pancreatic Development  
Several TFs are involved in the development of both exocrine and endocrine 
lineages in the pancreas, yet this section will focus solely on the major TFs involved in 
beta-cell formation (Figure 1.2). 
The first transition stage at e8.5 is characterized by the high expression of 
pancreatic duodenal homeobox 1 (Pdx-1), pancreas-specific transcription factor (Ptf1a), 
and SRY box 9 (Sox9) throughout the epithelial layer of the dorsal and ventral pancreatic 
buds (Burlison et al., 2009; Kawaguchi et al., 2002; Seymour & Sander, 2011). These 
three TFs are important in determining murine pancreatic fate during early development 
since pancreatic hypoplasia occurs with the absence of any one of the three TFs (Gittes, 
2009). Early expression (e9) of the LIM homeobox TF islet-1 (Isl1) is required in the 
pancreatic endoderm for subsequent generation of endocrine cells, and ablation of the 
Isl1 gene causes a near complete lost of the pancreatic mesenchyme and reduction of 
Pdx-1 expression in the developing embryo (Ahlgren et al., 1997; Du et al., 2009). The 
expression of Ptf1a, Forkhead box O1 (FoxO1), Nk2 homeobox 2 (Nkx2.2), and Nk6 
homeobox 1 (Nkx6.1) shortly follow the expression of Pdx-1 (Hald et al., 2008; Kitamura 
et al., 2009; Sander et al., 2000). Initial signs of endocrine differentiation are also seen 
during the first transition stage with the controlled expression of neurogenin 3 (Ngn3). 
Ngn3 is an important marker for endocrine precursor cells, yet these early first transition 
endocrine cells do not contribute to the adult islets (Pan & Wright, 2011). In contrast to 
the first transition stage, beta-cells formed in the second transition contribute to 
functioning mature islets (Gunasekaran et al., 2012).  
During the second transition stage, multipotent progenitor cells begin their 
commitment and differentiation towards an endocrine, acinar, or ductal cell fate by 
adopting either a tip or trunk confirmation based on signaling through the membrane 
receptor Notch (Afelik & Jensen, 2013; Nielsen et al., 1999). The presence of TFs Ptf1a 
and c-Myc with pancreatic enzyme carboxypeptidase A (Cpa) marks the tip domain, 
which eventually gives rise to the exocrine (acinar cells) portion of the pancreas. The 
extending trunk compartment, which gives rise to ductal and endocrine cells, expresses 
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Nkx6.1/6.2, Sox9, Tcf2, Onecut-1, Prox1, and Hes1 (Jacquemin, et al., 2003; Kopinke et 
al., 2011; Schaffer et al., 2013; Zhou et al., 2007). Controlled expression of Notch 
regulates the trunk compartment differentiation towards either a ductal or endocrine cell 
fate. When Notch is up-regulated, Hes1 represses Ngn3 and promotes ductal cell fate 
(Afelik & Jensen, 2013). Down-regulation of Notch signaling leads to decreased Hes1 
expression, allowing for Ngn3 expression to emerge in Sox9+ cells. Ngn3 marks the 
earliest progenitor of all endocrine cells in pancreas development and is central for the 
expression of other TFs that determine beta-cell lineage differentiation (Gradwohl et al., 
2000). Once Ngn3 expression is initiated, Ngn3+ cells delaminate and migrate away from 
the surrounding Sox9+ ductal tissue compartment into the mesenchyme for the initial 
formation of the endocrine clusters (Gradwohl et al., 2000; Johansson et al., 2007; 
Schwitzgebel et al., 2000). 
Nkx6.1 expression is required for beta-cell lineage during the second transition 
stage, where it promotes both beta-cell gene activation and down-regulation of TFs 
associated with other endocrine genes (Schaffer et al., 2013). The TFs 
musculoaponeurotic fibrosarcoma homolog A (MafA),  paired box 4 (Pax4), and 
neurogenic differentiation 1 (NeuroD1) are also important during beta-cell differentiation 
and are essential for survival in the emerging mature beta-cell (Collombat et al., 2003, 
2009; Nishimura et al., 2006; Yang et al., 2011).  
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Figure 1.2: Simplified model of pancreatic progenitor cell differentiation in the 
developing mouse pancreas 
Only major factors associated with the development of beta-cells are shown. The 
coloured shapes represent the differentiating cell types.  
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1.4 Islet Vascularization  
Although the endocrine compartment only contributes to 2% of the mature 
pancreas mass, almost 10-15% of the total pancreatic blood vessels from the coeliac and 
superior mesentery arteries vascularize the islet of Langerhans (Henderson & Moss, 
1985; Jansson & Hellerström, 1983). Islet vascularization is essential for the regulation of 
hormone secretion and blood glucose monitoring. High levels of vascular endothelial 
growth factor-a (Vegf-a) are observed in the beta-cells (Brissova et al., 2006; Watada, 
2010). Vegf-a increases angiogenesis during development through endothelial cell 
recruitment and aids in maintaining the islet vasculature in postnatal pancreata 
(Christofori et al., 1995; Reinert et al., 2013).  
Early signs of pancreatic perfused capillaries are observed at e10.5 and integration to the 
surrounding peripheral capillary bed as epithelial branching begins around e11.5-12.5 
(Pierreux et al., 2010; Shah et al., 2011). Ablation of blood vessels in the developing 
pancreatic bud, which can be induced through either aorta removal before bud formation 
or inhibition of Vegf receptor after budding, leads to the absolute failure of pancreas 
growth (Lammert et al., 2001; Magenheim et al., 2011). Importantly, vascular endothelial 
cells in the islets are responsible for the production of the basement membrane. Beta-cell 
proliferation is affected through the interaction of β1 integrin and the laminin ligand of 
the endothelial cell basement membrane (Nikolova et al., 2006). Additional work has 
found that the ECM interacts with islet vasculature to decrease the levels of intraislet 
endothelial cell death (Van Deijnen et al., 1992). Another in vivo study that subjected 
mice to subcutaneous transplantation of fibrin-enriched islets showed an increase in islet 
vessel count and neovascularization (Sabek et al., 2010). These studies demonstrate an 
interaction network between the islet vasculature, ECM, and β1 integrin that maintains 
islet vascularization and survival. 
1.5 Diabetes Mellitus  
Diabetes mellitus is a metabolic disorder where the body does not produce insulin 
or improperly utilize the endogenous insulin. This in turn could cause elevated blood 
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glucose level which may potentially harm blood vessels, nerves and organs. 
Hyperglycemia develops due to abnormal insulin production and/or the emergence of 
peripheral insulin resistance. Type 1 diabetes (T1D) is caused by an autoimmune 
response by the T-cells towards insulin producing beta-cells. As a result, T1D patients 
lose the majority of functional beta-cell mass and rely on an exogenous insulin source to 
regulate glucose levels. In contrast, the pathogenesis of type 2 diabetes (T2D) can arise 
from multiple factors that result in a hyperglycemia-induced compensatory insulin 
production response and peripheral tissue insulin resistance. The general onset of T2D 
are slower to progress and primarily in inactive obese adults with the initial reduced 
sensitivity to insulin. The beta-cells initially expand as a compensatory mechanism but 
eventually fail with the prolonged demand for insulin, leading to reduced beta-cell mass 
and insulin production. Various treatments are available for T2D patients, including 
pharmaceutical and lifestyle management in diet and reduction of body weight. However, 
late-stage cases may eventually require exogenous insulin.  
The Edmonton protocol, first established at the University of Alberta, was designed to 
restore functional beta-cell mass to T1D patients by transplanting healthy isolated islets 
from cadaver donors into the hepatic portal vein of immunosuppressed recipients. This 
treatment has shown promising success in inducing short-term (1-5 years) insulin 
independence in patients, yet most islet recipients revert back to insulin dependence after 
five years due to multiple factors, with recurring autoimmune responses and allograft 
rejection as the main factors behind their loss in insulin independence (Shapiro, 2012). 
This protocol is also limited by the lack of donors and the success rate of isolating a 
sufficient number of healthy islets (Shapiro et al., 2000). Common issues that arise from 
removing donor islets from their micro-environment are the disruption of vasculature, the 
development of reduced beta-cell mass and function, and the promotion of islet cell death 
(Ryan et al., 2005). Additional difficulties that occur with prolonged cultures of isolated 
islets ex vivo are a high level of senescence, loss of the islet architecture, and a reduction 
in insulin expression (Halvorsen et al., 2000). A possible solution to extend islet survival 
would be to design an islet micro-environment that optimizes islet cell-ECM interactions. 
Integrin receptors are one of the major receptors that regulate key cell-ECM 
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communication pathways and adhesion, and optimizing their expression in islets could 
lead to improved viability and insulin secretion. 
1.6 Integrin and ECM  
1.6.1 ECM 
Integrin function is dependent on its extracellular attachment to the ECM. The 
ECM is a highly dynamic non-cellular component found ubiquitously in all organs. It 
provides a physical scaffold and essential biochemical signals required for cell 
differentiation, survival, and morphological architecture (Frantz et al., 2010; Shih et al., 
2016; Stendahl et al., 2009).  
The arrangement and composition of the ECM differs slightly among tissue types. 
However, the core function in providing cellular support remains constant among 
different tissue. Proteoglycans and fibrous proteins make up most of the ECM and forms 
a hydrated gel that fills the interstitial space (Stendahl et al., 2009). Fibronectins, 
laminins, collagens, and vitronectin (VN) are the main ECM adhesion protein in the 
pancreas, and each protein serves as a specific ligand through which integrin receptors 
will bind to.   
1.6.2 Integrin 
Integrins are a family of cell adhesion receptors that interact with the ECM and 
incorporate both extra- and intracellular processes. Integrins are composed of an a and b 
subunit. There is a small cytoplasmic tail of less than 50 amino acid and an ectodomain 
protein size of about 1200 amino acids for the a subunit and 800 amino acids for the b 
subunit (Bouvard et al., 2001; Humphries et al., 2012). The family of mammalian 
integrins consist of 18a and 8b subunits that can combine to 24 unique heterodimeric 
forms of integrin (Takada et al., 2007). Each heterodimeric integrin complex has a 
different degree of affinity towards various ECM ligands and are categorized based on 
their affinities. The extracellular ligand –binding a subunit stimulates intracellular 
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cytoskeletal remodeling and signaling through the b subunit (‘outside-in’), while 
signaling cues through the b subunit leads to a subunit (‘inside-out’) (Barczyk et al., 
2010; Takada et al., 2007). Nuclear magnetic resonance spectrometry has shown a 
combination of electrostatic and hydrophobic interactions between the cytoplasmic tails 
of the α and β integrin subunits that regulate inside-out signaling (Qin et al., 2004; Ulmer 
et al., 2001; Vinogradova et al., 2002; Weljie et al. , 2002). 
b1 associates with a3, a6, a7, a5, aV, and a8 to selectively bind to the laminin (LM) 
and fibronectin (FN) group of glycoprotein containing the Arg-Gly-Asp (RGD) motif in 
their structure (Minton, 2013). b2 integrin primarily associates with aL, aM, aX, and 
aD, which allows for leukocytes in the extracellular matrix to interact with endothelial 
cells and deliver a diverse range of cellular responses (Harris et al., 2000). Even with the 
existence of multiple different classes of integrin, there is a large overlap in ligand 
binding preference. Therefore, there is no limitation towards binding to a single specific 
ligand type (Boudreau & Jones, 1999; Lee & Juliano, 2004). This overlap in numerous 
ligand preferences depends on integrin affinity, which is determined based on if the 
heterodimer is in an inactivated (low-affinity) or activated (high-affinity) conformation. 
The major integrin -associated downstream nonreceptor adhesion complex of focal 
adhesion kinase (FAK) facilitates the activation of intracellular signaling pathways, 
including the protein kinase B (Akt) and Ras pathways. FAK directly binds with the 
actin-binding protein talin and kindlin, which are both important in activating and linking 
integrin to the actin cytoskeleton. Inside-out signaling begins with talin binding to the 
cytosolic domain of the b integrin subunit. This activates the kindlin protein family, 
which in turn changes the integrin into a high-affinity conformation (Shattil et al., 2010). 
The accessible high-affinity state of the integrin allows for extracellular ligand binding, 
promoting outside-in signaling and an additional cascade of downstream integrin -
associated pathways (Takagi et al., 2002).  
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1.7 β1 integrin subfamily 
β1 integrin associates with 12 different types of α subunits (α1- α11 & αV), 
making it the largest subfamily of integrins with different ligand binding specificity 
(Barczyk et al., 2010; Fassler & Brakebusch, 2005). The association of β1 integrin with 
different α subunits is highlighted in Figure 1.3 (Gahmberg et al., 2010).  The 
cytoplasmic domain contains the highly conserved NPxY motif responsible for 
controlling inside-out activation. The cytoplasmic tail of β1 integrin does not contain an 
actin binding site or any enzymatic capabilities. Instead, attachment to the actin 
cytoskeleton for β1 integrin is mediated by four different protein complexes of α-actinin, 
talin, filamin, and integrin linked kinase (ILK) (Fassler & Brakebusch, 2005). 
Several key signaling pathways of the FAK/MAPK/ERK and PI3K/Akt are mediated by 
β1 integrin and have been confirmed in a variety of studies using both in vivo and in vitro 
models (Hammar et al., 2004; Peart et al., 2017; M. Riopel et al., 2011; Saleem et al., 
2009). It is through this bi-directional signaling pathway in which β1 integrin controls 
cell proliferation, differentiation, and survival.  (Cordes et al., 2006; Wennerberg et al., 
2000). These intracellular protein complexes act as a binding platform for other 
cytoskeletal and signaling molecules.  
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Figure 1.3: β1 associations with α integrin subunits. 
α subunits highlighted with red indicate the major integrin associations that are involved 
in islet development with their preferred ECM ligand binding partner. α subunits 
highlighted with blue indicate integrin association found outside the beta-cells. (VN= 
Vitronectin, FN= Fibronectin, LM= Laminin) (Adapted from Gahmberg et al., 2010) 
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1.7.1 β1 integrin in pancreas development  
Early studies have shown the lethal effect of β1 integrin gene ablation during 
morphogenesis, where the inner cell mass fails to form in the late blastocyst stage 
(Stephens et al, 1995). In vitro work that assessed the role of β1 integrin during pancreas 
development has shown that isolated human fetal islets at 19-21 weeks of gestational age 
preferentially adhered to a collagen IV matrix through integrin α1β1, and a similar 
pattern was observed with fetal beta-cell adhesion to vitronectin through αVβ1 integrin 
(T. Kaido et al., 2004). Previous studies from our lab have shown the effect of β1 integrin 
on islet cell survival, maturation, and proliferation during pancreas development in both 
rat and human models. The developing endocrine cells in the human and murine pancreas 
express integrins α3β1, α5β1, and α6β1, with increased levels of mRNA and protein for 
these integrin heterodimers by 16-20 weeks and e18-p21 days, respectively (Yashpal et 
al., 2005).  
The role of β1 integrin receptor during pancreatic development was further studied using 
an immunoneutralizing blocking antibody, and this resulted in inhibited adhesion of 
cultured fetal human and rat islets to collagen I, fibronectin, and laminin matrices. 
Blocking β1 integrin also reduced Insulin mRNA levels and increased islet cell death in 
both rat and human models (Wang et al., 2005; Yashpal et al., 2005). Similar to the β1 
integrin blocking study, subsequent studies that specifically blocked the a3 subunit 
demonstrated inhibited human fetal islet cell adhesion to collagen I and IV matrices, with 
reduced proliferation and Pdx-1 and insulin expression (Krishnamurthy et al., 2011). 
However, the PI3K/Akt pathway was only affected by a3 blockade and not β1 blockade, 
indicating that signaling pathways are specific to different integrin subunits during early 
human development. As mentioned, β1 integrin has also been shown to be involved in 
the FAK/MAPK/ERK downstream signaling pathway in human fetal pancreatic islet cells 
(Saleem et al., 2009).  
The study of a rat insulin (insulin 2) promoter β1 integrin knockout mouse model 
(RIPβ1KO), which results in the loss of β1 integrin specific to developing mouse beta-
cells, showed a significant reduction in beta-cell mass, indicating that β1 integrin 
15 
 
promotes expansion of the beta-cell compartment (Diaferia et al., 2013). In addition, 
global gene expression analysis revealed reduced expression of genes that function as 
positive regulators of cell cycle progression. The findings from this study indicate that the 
interactions between the ECM and beta-cell β1 integrin play an important role in ensuring 
sufficient islet proliferation and expansion during pancreatic development.  
1.7.2 β1 integrin in islet survival and function  
Formative in vitro work that looked at β1 integrin’s role in islet survival was 
completed using the RIN-2A cell line, originally derived from rat islet cells (Kantengwa 
et al., 1997).  Both the primary and transformed cells showed the presence of β1 integrin, 
and blocking β1 integrin led to a reduction in cell spreading and attachment to the ECM 
(Kantengwa et al., 1997). A follow-up immunodepletion study indicated that the α3β1 
heterodimer constituted approximately half of total β1 integrin expressed in the primary 
rat islet cells. Isolated islets also require β1 integrin-ECM interactions to promote their 
survival in vitro. The survival of isolated islet cells was vastly improved when cultured 
with collagen I and fibronectin, which are prominent ligands of β1 integrin. Anti-β1 
integrin antibody treatment in isolated rat islets on tumor derived basement membrane 
producing  804G matrix resulted in reductions for both beta-cell spreading and 
phosphorylation of focal adhesion kinase (Parnaud et al., 2006). In addition, the 
spreading of beta-cells was also reduced when the interaction between β1 integrin and 
laminin-5 was blocked, which led to a lower level of insulin release. The 804G matrix 
protected against beta-cell apoptosis through the increased activation of the 
FAK/MAPK/ERK1/2 pathway (Hammar et al., 2004). 
Insulinoma-1 (INS-1) cells, derived from irradiated rat insulinoma cells, have been 
extensively utilized in literature due to their functional characteristics that mirror 
pancreatic beta-cells, including their similar physiological release of insulin in response 
to glucose stimulation (Asfari et al., 1992; Skelin et al., 2010). α3β1 is highly expressed 
in INS-1 cells, but other β1 integrin associations (α1-α6 and αV expression) have also 
been identified (Krishnamurthy et al., 2008). Culturing the INS-1 cells on collagen I and 
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IV also significantly increased spreading, proliferation, adhesion, and FAK 
phosphorylation, while blocking α3β1 integrin diminished these effects.  
The generation of different knockout mouse models has allowed for investigation into the 
role of β1 integrin on adult islet physiology and interactions between the ECM and beta-
cells. A conditional knockout mouse model of β1 integrin in collagen 1a2 (col1a2)-
producing cells, commonly expressed in connective tissue, bone, and tendon, was 
developed (β1KO mice) (Riopel et al., 2011). This model utilized the tamoxifen –induced 
CreERT-loxP system to knockout β1 integrin at 3 weeks of age. Adult male β1KO mice 
developed glucose intolerance, reduced beta-cell mass and proliferation, and increased 
beta-cell apoptosis (Riopel et al., 2011). Decreased phosphorylation of FAK and ERK 
were also shown in β1KO islets, indicating that the loss of β1 integrin negatively affected 
FAK/MAPK/ERK signaling required for beta-cell function. Furthermore, β1KO islets 
physically dissociated from surrounding exocrine tissue, demonstrating the involvement 
of β1 integrin towards maintaining endocrine architecture in vivo. However, the model 
was limited in its study of beta-cell -specific β1 integrin loss since the knockout was not 
exclusively localized to beta-cells.   
The RIPβ1KO mouse model (β1 integrin knockout specific to the beta-cells by rat insulin 
promoter) produced a reduction in beta-cell mass in adult mice (Diaferia et al., 2013). In 
contrast to the previous study that induced knockout at adulthood, the β1 integrin 
knockout in RIPβ1KO mice is present as soon as the Ins-2 gene is expressed at e8.0 
during pancreas development (Diaferia et al., 2013; Jiang et al., 2010).  Similar to 
previous in vitro studies, isolated RIPβ1KO pancreatic cell clusters had impaired 
adhesion to the 804G matrix. Even though a significant reduction of beta-cell mass was 
noted in mice at 8 weeks, RIPβ1KO mice did not develop a diabetic phenotype and 
displayed normal glucose responses. This study suggested that this may be due to 
compensatory upregulation through other β subunits, including β3, β4, and β5 integrin 
receptors.  
A more recent study using a postnatally -induced mouse insulin promoter (MIP)-CreER 
knockout of β1 integrin in beta-cells (MIPβ1KO) demonstrated impairments in glucose 
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tolerance and a reduction in beta-cell mass, islet density, insulin release, and beta-cell 
proliferation in male adult mice 8 weeks post-induction (Peart et al., 2017). 
Phosphorylation of signaling molecules FAK, ERK, and Akt were reduced in isolated 
MIPβ1KO islets. Furthermore, MIPβ1KO female mice similarly developed glucose 
intolerance after 16 weeks post-induction. These findings are consistent with the findings 
from the inducible col1a2 promoter β1KO mice. Unlike the earlier β1KO and RIPβ1KO 
studies, inducible MIPβ1KO mice are an improved appropriate model for temporal 
control of beta-cell specific loss of β1 integrin. However, the compensatory response 
postulated in the RIPβ1KO study was not observed in MIPβ1KO mice. These 
discrepancies may be due to a specific temporal role of beta-cell β1 integrin during beta-
cell development and maturation, and thus emphasizes the need for an in vivo mouse 
model with an inducible beta-cell specific knockout of β1 integrin.  
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1.8 Rationale, Objective and Hypothesis  
Proper pancreas growth and remodeling is crucial for the development of 
functional beta-cells that maintain glucose metabolism. Pancreatic islet development is 
enriched by the dynamic interaction between the ECM and integrin receptors. Previous 
studies have suggested the importance of β1 integrin in pancreas embryogenesis. 
Although reduced postnatal beta-cell mass was noted in all mouse models with β1 
integrin knockout, the presence of glucose intolerance differed between models based on 
the stage of beta-cell development that β1 integrin was lost (Diaferia et al., 2013; Peart et 
al., 2017; Riopel et al., 2011). In contrast to the RIPβ1KO study, this project will use a 
tamoxifen-inducible β1 integrin knockout model with Cre recombinase downstream to 
the mouse insulin promoter (MIP). The use of MIP over RIP –driven recombination will 
eliminate the potential off-target knockout of β1 integrin in the RIP -expressing 
hypothalamic tissue (Tamarina et al., 2014; Wicksteed et al., 2010). The proposed study 
will examine inducing beta-cell β1 integrin knockout at the start of the second transition 
stage of pancreas development, a window for major beta-cell differentiation and 
proliferation during the development. This is in contrast to previous study where 
knockout was induced in adult mice.  
Objective  
To determine the role of β1 integrin in mouse fetal pancreatic beta-cell 
differentiation, proliferation, and survival during the second transition stage of pancreas 
development. 
Hypothesis 
The ablation of β1 integrin in beta-cells at the second developmental transition 
stage will impair beta-cell differentiation, migration, and proliferation.  
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Specific Questions 
1. Does the frequency of tamoxifen administration affect the percentage of β1 
integrin knockout in MIPβ1KO beta-cells? 
2. Does a beta-cell specific β1 integrin knockout perturb beta-cell proliferation and 
apoptosis at the end of the second transition stage? 
3. Is beta-cell formation from the ductal compartment affected in MIPβ1KO mice? 
4. Does the expression of beta-cell specific transcription factors and signaling 
change in MIPβ1KO mice? 
5. Is islet vascularization affected in MIPβ1KO mice? 
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Chapter 2 – Material and Methods 
2.1 Generation of temporally -induced fetal MIPβ1KO mouse 
model 
B6;129-Itgb1tm1Efu/J (β1itgfl/fl) and Tg(Ins1-Cre/ERT)1Lphi (MIP-CreERT) mice 
were obtained from Jackson Laboratories (Bar Harbor, MA, USA; stock number: 
004605) and Dr. Louis Philipson’s laboratory (University of Chicago, Chicago, IL, 
USA), respectively, and crossed to produce heterozygous MIP-CreERT+/-; β1itgfl/+ mice 
(Peart et al., 2017). MIP-CreERT mice were crossed with the B6.Cg-
Gt(ROSA)26Sortm9(CAG-tdTomatro)Hze/J reporter mouse line (stock number: 007909, Jackson 
Laboratories, Bar Harbor, ME, USA) to confirm that Cre recombinase activity was 
specific to beta-cells (Trinder et al., 2016). MIP-CreERT+/-; β1itgfl/+ mice were further 
crossbred to produce both tamoxifen-inducible β1 integrin knockout (MIPβ1KO, MIP-
CreERT+; β1itgfl/fl)  and control (Control, MIP-CreERT-; β1itgfl/fl and MIP-CreERT+; 
β1itg+/+) offspring (Figure 2.1).  
Tamoxifen (³99%, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 100% ethanol 
at 60oC. For ease of delivery and dilution purposes, corn oil (Sigma-Aldrich) was mixed 
with ethanol-dissolved tamoxifen to yield a final concentration of 30 mg/mL. Tamoxifen 
was administered at 6 mg/ 40 g of body weight (BW) through oral gavage to pregnant 
heterozygous or mutant MIPβ1KO dams during the 2nd transitional stage of fetal pancreas 
development (Figure 2.2). The tamoxifen dosage frequency was subsequently increased 
to three doses (3x) for three consecutive days from e13.5-15.5. Due to the high fetal 
toxicity observed with 3x tamoxifen administration, the dosage was reduced to two doses 
(2x) administered at e13.5 and e15.5.  
Fetuses were collected from euthanized pregnant mothers at e19.5. Fetal body weights 
were recorded and tail snips were collected for genotyping. Pregnant mice were initially 
given a single dose of tamoxifen (1x) at e13.5, but low β1 integrin knockout levels were 
observed through histological quantification (Figure 3.4A).  Pancreata were dissected and 
weighted from all pups for protein extraction or histological analysis. Tamoxifen induced 
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fetal pancreas collection was done using control samples from controls (MIP-CreERT-; 
β1itgfl/fl and MIP-CreERT+; β1itg+/+) and the experimental MIPβ1KO (MIP-CreERT+/-; 
β1itgfl/+).  Fetus blood samples were also collected for measuring glucose and insulin 
levels. An enzyme linked immunosorbent assay (ELISA) kit (ALPCO, Salem, NH, USA) 
was used to measure circulating plasma insulin content. 
All protocols were approved by the Animal Use Subcommittee at the University of 
Western Ontario in accordance with the guidelines of the Canadian Council of Animal 
Care (Appendix I). All mice were allowed ad libitum access to food (Irradiated 2919, 
Harlan Tekard, Indianapolis, IN, USA) and water in a constant ambient temperature of 
20oC with 12-hour day/night cycles. 
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Figure 2.1: Breeding strategy for generation of MIPβ1KO mice. 
Generation of crossing MIP-CreERT+ mice with B6;129-Itgb1tm1Efu/J  to produce 
heterozygous MIP-CreERT+/-;Itgb1fl/+ breeding pairs. The experimental mice are either 
MIPβ1KO (MIP-CreERT+;Itgb1fl/fl, red) or controls (MIP-CreERT+;Itgb1+/+ and MIP-
CreERT-;Itgb1fl/fl, blue) (Peart et al., 2017). The expected frequency of offspring from 
MIP-CreERT+/-;Itgb1fl/+ pairs, with the expected experimental genotypes displayed 
below. 
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Figure 2.2: Schematic of beta-cell β1 integrin knockout (MIPβ1KO) in accordance 
with important pancreas development stages in developing murine embryos. 
The three transitional stages in mouse pancreas development are outlined above with the 
start at embryonic day 8.5 (e8.5). Pregnant females were administered different 
tamoxifen dosages via oral gavage between e13.5-e15.5. Fetal mice were dissected for 
pancreas collection at e19.5.  
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2.2 Genotyping of the MIPβ1KO mouse line  
Tail samples from fetal (e19.5) mice were incubated in base solution (25 mM 
NaOH; 0.2 mM ethylenediaminetetraacetic acid) and heated for 30 minutes at 95°C for 
DNA extraction. 40mM Tris-HCL (pH 5.5) was subsequently added to neutralize the 
solution. 1 µL of each DNA sample was used to perform a 26-cycle polymerase chain 
reaction (PCR) with primer pair of MIP& CreER and oIMR1906 & oIMR1907 primers 
(Table 1). PCR products were determined using gel electrophoresis (1.5% agarose gel 
stained with ethidium bromide) and were visualized using the Gene Genius Bio Imaging 
System (SynGene, Frederick, MD, USA) and GeneSnap 7.12 software (SynGene; 
Cambridge, England). Bands at 268 base pairs (bp) were observed in MIPCreERT+ mice. 
Genotypes for the β1itg PCR product were obtained based on the DNA fragment size: 
160bp alone (β1itg+/+), 280bp alone (β1itgfl/fl), or at both 160bp and 280bp (β1itgfl/+) 
(Figure 2.3).  
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Figure 2.3: PCR genotyping of fetal mice 
(A) Band products for MIPCreERT+ mice (268 bp). The absence of a band at 268 bp 
denotes a MIPCreERT - (blue box) mouse. (B) Itgβ1 mice homozygous for floxed alleles 
at 280bp (Itgβ1fl/fl, red arrow), homozygous for wildtype alleles at 160bp (Itgβ1+/+, blue 
arrow), or heterozygous for both the wildtype and floxed allele with two bands at 160bp 
and 280bp (Itgβ1fl/+, green arrow).  
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2.3 Tissue processing and histological analyses 
Fetal pancreata were fixed in 4% paraformaldehyde (PFA) overnight at 4o C. 
Pancreata were embedded in paraffin wax following a series of dehydration steps using 
ethanol and toluene gradients (Shandon CitadelTM Tissue Processor, Citadel 1000, 
Thermo Electron Corporation; Waltham, MA, USA). The entire length of the pancreatic 
blocks were cut into single sections at a thickness of 4 µm using a microtome (Leica 
RM2245, Leica Biosystems). Tissue sections were dried on a 37o C slide warmer 
chamber overnight.  
For immunofluorescence and immunohistochemical staining, sections were deparaffined 
in a series of xylene and ethanol washes. Heat-induced antigen retrieval was conducted 
using a sodium citrate antigen retrieval solution (pH 6.0). To prevent non-specific 
antibody binding, slides were treated with blocking solution containing 10% goat serum 
(Invitrogen; Carlsbad, CA, USA) for 30 minutes at room temperature. Sections were 
stained using primary antibodies with their indicated dilution (Table 2) and incubated 
overnight at 4o C. For immunofluorescence staining, fluorescein isothiocyanate (FITC) 
and tetramethyl rhodamine isothiocyanate (TRITC) conjugated secondary antibodies 
(Jackson Immunoresearch Laboratories; West Grove, PA, USA) were used at a 1:50 
dilution (Table 2). 4'-6'-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) counterstain 
was administered to label cell nuclei. Visualization was done using a Leica LMIRE2 
fluorescence microscope and Image ProPlus software (MediaCybernetics). 
Immunohistochemical staining utilized a streptavidin-biotin horseradish peroxidase 
secondary antibody complex with aminoethyl carbazole substrate (Invitrogen) after initial 
incubation of primary antibodies. Hematoxylin was used to counterstain for cell nuclei. 
2.4 Morphometric analysis of histological sections 
Morphometric analysis of the islets in fetal tissue sections were done using Image 
ProPlus software (MediaCybernetics). An islet was defined as a group of cells with at 
least three or more insulin+ cells and one glucagon+ cell. For quantification of islet 
density, islet number per pancreatic section was counted and divided to the total pancreas 
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area and data were expressed as islet number per mm2. Islet area was determined by 
manually tracing all the islets on the section for each experimental sample. The percent 
islet area was calculated by the total islet area over the total area of the pancreas section. 
For measurement of beta cell and alpha cell mass, manually tracing insulin+ or glucagon+ 
areas were performed and calculated as follows: alpha or beta cell mass (mg) = [beta or 
alpha cell area x pancreas mass (mg)]/pancreas area (Wang et al. 1994).  
The presence of transcription factors in ductal and beta cells was conducted using double 
immunofluorescence staining for Pdx-1 or insulin with pan-cytokeratin (pan-CK), 
respectively. Quantification was completed by manually counting the total number of 
double positive cells in the total pan-CK+ or insulin+ cell populations.  
Islet microvasculature was labeled using the endothelial cell marker platelet endothelial 
cell adhesion molecule (PECAM-1). Sections were co-stained with insulin to visualize 
capillaries in the islets. Total islet capillary area (PECAM-1+/insulin+) was manually 
traced and divided over total insulin+ area. The islet capillary density was measured by 
tabulating the total number of islet capillaries over the total islet area. All islets on a 
section were analysed and a minimum of four pancreata per experimental group was 
used. 
2.5 Protein extraction and western blot analyses 
Fetal pancreata were sonicated in Nonidet-P40 lysis buffer (Nonidet-P40, 
phenylmethylsulfonyl fluoride, sodium orthovanadate) (Sigma-Aldrich) containing a 
completeTM protease-inhibitor coctait tablet (Roche Applied Science, Quebec City, QC, 
Canada). Samples were spun down for 20 minutes at 4oC and supernatants were stored at 
-80 OC. Protein concentration was determined using a Bradford assay with Bio-Rad dye 
reagent (Bio-Rad Laboratories, Mississauga, ON, Canada). The absorbance of the 
microtiter plate was read at 595nm using a Multiskan Spectrum spectrophotometer 
(Thermo Scientific). Protein lysates were loaded at an equal concentration (15-20 µg) per 
well on either a 5, 7.5, 10, or 12% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) 
running gel. Gels were transferred onto nitrocellulose membranes (Bio-Rad 
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Laboratories), and the transfer process was done in a cold chamber with transfer buffer 
composing of glycine (192 mM), Tris (25 mM), and methanol (20% v/v) at a constant 
current of 250 mA for 180 minutes. Ponceau S stain was applied to the nitrocellulose 
membrane and the gels were treated with Coomassie blue followed by destaining solution 
to assess the quality of protein transfer. Membranes were washed in Tris buffered saline 
with 0.1% Tween-20 (TBST) solution and blocked in a 5% non-fat dry milk blocking 
solution for 1 hour at room temperature to prevent non-specific binding. Membranes 
were treated with diluted primary antibodies (Table 1) at room temperature for 2 hours or 
overnight at 4oC. Secondary anti-rabbit or anti-mouse horse radish peroxidase -
conjugated antibody (Cell Signaling; Temecula, CA, USA) was applied for 1 hour at 
room temperature before visualization with a chemiluminescence ECLTM-Plus Western 
Blot detecting reagent (PerkinElmer, Wellesley, MA, USA). Images were taken using the 
Versadoc Imaging System (Bio-Rad Laboratories) and Quantity One software (Bio-Rad 
Laboratories). The protein of interest was normalized to the loading control protein on the 
same membrane. Imaged protein bands on the membrane were quantified using 
densitometric analyses with Image Lab 3.0 software (Bio-Rad Laboratories). 
2.6 Statistical Analysis  
Data is presented as means ± SEM with data of n ³ 3 or means ± SD with data of 
n=2. Statistical analysis was done using a two-tailed unpaired Student’s t-test with 
GraphPad Prism 6 (GraphPad software; La Jolla, CA, USA). Differences were considered 
statistically significant when p<0.05.  
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Table 1: List of Primers used for Polymerase Chain Reactions 
Primer Name Primer Pair Sequence 
oIMR1906 5’-CGG CTC AAA GCA GAG TGT CAG TC-3’ 
oIMR1907 5’-CCA CAA CTT TCC CAG TTA GCT CTC-3’ 
MIP 5’- CCT GGC GAT CCC TGA ACA TGT CCT - 3’  
CreER 5’- TGG ACT ATA AAG CTG GTG GGC AT - 3’  
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Table 2: Primary and Secondary antibodies used for Immunostaining and Western-
Blot Analysis. 
Primary Antibodies  Dilution Company  
Anti-Akt Rabbit polyclonal 1:3000* Cell Signaling (Temecula, CA, 
USA) 
Anti-Caspase 3 Rabbit polyclonal  1:1000* Cell Signaling (Temecula, CA, 
USA) 
Anti-cleaved Caspase-
3 (Asp175) 
Rabbit polyclonal  1: 2000* Cell Signaling (Temecula, CA, 
USA) 
Anti-ERK Rabbit polyclonal 1:3000* Cell Signaling (Temecula, CA, 
USA) 
Anti-GAPDH Rabbit polyclonal  1: 2000* Santa Cruz (Santa Cruz, CA, 
USA) 
Anti-Glucagon Mouse polyclonal 1:800 Sigma-Aldrich (St Louis, MO, 
USA) 
Anti-Glut2 Rabbit polyclonal 1:200 Abcam (Cambridge, MA, USA) 
Anti-Insulin Mouse polyclonal 1:800 Sigma-Aldrich (St Louis, MO, 
USA) 
Anti-Insulin Rabbit polyclonal 1:50 Santa Cruz (Santa Cruz, CA, 
USA) 
Anti-Integrin β1 Rabbit polyclonal 1:500* Abcam (Cambridge, MA, USA) 
Anti-Integrin β1 Rat 1:100 Milipore (Etobicoke, ON, CA) 
Anti-Islet-1 Mouse polyclonal 1:100 DSHB (Iowa City, USA) 
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Anti-Ki67 Rabbit polyclonal 1:100 Abcam (Cambridge, MA, USA) 
Anti-MafA Rabbit polyclonal 1:100 Bethyl Laboratory 
(Montgomery, TX, USA) 
Anti-Nkx6.1 Mouse polyclonal 1:100 DSHB (Iowa City, IA, USA) 
Anti-p53 Mouse 
monoclonal 
1:2000* Cell Signaling (Temecula, CA, 
USA) 
Anti-pan-Cytokeratin Mouse 
monoclonal 
1:50 Santa Cruz (Santa Cruz, CA, 
USA) 
Anti-Pdx-1 Rabbit polyclonal 1:800 Dr. Wright (University of 
Vanderbilt, Nashville, TN, 
USA) 
Anti-pancreatic 
polypeptide 
Zymed 1:50 Thermofisher (Waltham, MA, 
USA) 
Anti-PECAM Rabbit polyclonal 1:200 Santa Cruz (Santa Cruz, CA, 
USA) 
Anti-phospho-Akt 
(Ser473) 
Rabbit polyclonal 1:2000* Cell Signaling (Temecula, CA, 
USA) 
Anti-phospho-p53 
(Ser15) 
Rabbit polyclonal  1:1000* Cell Signalling (Temecula, CA, 
USA) 
Anti-phospho-ERK 
(Thr202/Tyr204) 
Rabbit polyclonal 1:3000* Cell Signaling (Temecula, CA, 
USA) 
Anti-Somatostatin Rabbit polyclonal  1:50 Thermofisher (Waltham, MA, 
USA) 
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Anti-β-actin Mouse polyclonal 1:5000* Sigma-Aldrich (St Louis, MO, 
USA) 
Secondary 
Antibodies 
 Dilution Company 
Horseradish 
peroxidase-linked 
secondary antibodies 
Broad Spectrum 1:1 (no 
dilution) 
Invitrogen (Carlsbad, CA, USA) 
Anti-mouse secondary 
antibody  
Goat polyclonal 1:50 JRL (West Grove, PA, USA) 
Anti-rabbit secondary 
antibody  
Goat polyclonal  1:50 JRL (West Grove, PA, USA) 
*dilution factor for western blot analysis. DSHB (Developmental Studies Hybirdoma 
Bank); JRL (Jackson Immunoresearch Laboratories) 
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Chapter 3 - Results 
3.1 Tamoxifen dosages on fetal body weight, premature birth 
rate, and intrauterine death at e19.5.  
To determine the effective dosage of tamoxifen on pregnant mice and to induce 
an appropriate knockout of β1integrin in fetuses, a single (1x), two (2x), or three (3x) 
dose(s) of tamoxifen were given via gavage from e13.5 to e15.5. A higher rate of 
premature birth before e19.5 (60% of pregnancies) was observed in the 3x oral tamoxifen 
dosage treatment when compared to 1x and 2x groups (Figure 3.1A). The number of 
fetuses found dead in utero at e19.5 was also higher in pregnant female mice 
administered with 3x tamoxifen dosage (Figure 3.1B), with close to 30% of total 
dissected litters displaying abnormal development. The common abnormalities observed 
included in utero death, and discoloured or darkened skin. Internal coagulated blood 
surrounding the pancreas region was also observed in these irregular fetuses. However, 
no difference in fetal body weight and pancreas weight was observed between control 
and MIPβ1KO at the time of dissection (e19.5), indicating that the number of tamoxifen 
dosages administered did not affect overall body and pancreas weight (Figure 3.1C and 
3.1D). Thus, subsequent experiments examined control and MIPβ1KO fetuses with 1x or 
2x tamoxifen dosage(s). In addition, we measured fetal blood glucose level and found no 
significant difference between the control, MIPβ1KO, and heterozygous circulating blood 
glucose level in the 2x tamoxifen group (Figure 3.2A). An ELISA also showed a similar 
level in plasma insulin between the control and MIPβ1KO groups (Figure 3.2B). 
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Figure 3.1: Different tamoxifen dosages on fetal MIPβ1KO mice premature birth, 
intrauterine death rates, body weight, and pancreas weight at e19.5.  
(A) Proportion of premature births for all tamoxifen induced pregnant mice (1x n=7, 2x 
n=28, 3x n=8 pregnancies per group). (B) Proportion of intrauterine dead fetuses in each 
litter (1x n=7, 2x n=19, 3x n=4 litters per group). (C) Body and (D) pancreas weight of 
fetal MIPβ1KO and control mice were measured at the time of fetal dissection (Body: 1x 
n=7, 2x n=23, 3x n=5 fetuses per group, Pancreas: n= 13-14 fetal pancreata per group). 
Data are expressed as means ± SEM. 
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Figure 3.2: Blood glucose and plasma insulin content on fetal MIPβ1KO and control 
mice at e19.5 with 2x tamoxifen dosage.  
(A). Blood glucose level in control, MIPβ1KO, and heterozygous groups (n=4-9 fetuses 
per group). Data are expressed as means ± SEM.  (B) Plasma insulin content in control 
and MIPβ1KO groups. Data are expressed as means ± SD (n=2 fetuses per group). White 
bars, control; grey bars, heterozygous; black bars, MIPβ1KO. 
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3.2 Efficiency of b1 integrin knockout in beta-cells of fetal 
MIPb1KO mice.  
To determine the efficiency of beta-cell β1 integrin knockout, 
immunofluorescence and western blot analysis of β1 integrin expression in fetal 
pancreata was performed to compare the percentage of knockout achieved with different 
tamoxifen administration. About 56% of β1 integrin staining in beta-cells was lost in 
MIPβ1KO fetal pancreata administered with 2x tamoxifen dosage when compared to 
control fetuses, determined by co- immunofluorescence of β1 integrin and insulin (p < 
0.05 vs. controls, Figure 3.3A and 3.3B). However, only a 20% reduction of β1 integrin 
staining in MIPβ1KO beta-cells given the 1x tamoxifen dosage was found, indicating a 
weaker recombinase activity (p < 0.05 vs. controls, Figure 3.4A). Western blot analysis 
of whole fetal pancreas samples showed a significant reduction (56%) in β1 integrin 
protein level in MIPβ1KO pancreata administered the 2x tamoxifen dosage (p < 0.05, 
Figure 3.3). Pancreata collected from the 3x tamoxifen dosage showed a 50% reduction 
in β1 integrin (Figure 3.4B). Since the tamoxifen dosage affects both the efficiency of β1 
integrin recombinase activity and toxicity in fetuses, the 2x dosage was selected for all 
subsequent experimental studies.  
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Figure 3.3: Efficiency of fetal beta-cell specific β1 integrin knockout. 
(A) Representative double immunofluorescence image (top) and quantification (bottom) 
of β1 integrin+ beta-cells after 2x tamoxifen administration in MIPβ1KO and control 
fetuses (n=5 pancreata per group). Scale bar: 25 µm. (B) Representative western blot 
image (right) of β1 integrin protein level in fetal MIPβ1KO and control pancreata (n=5 
pancreata per group). β1 integrin protein levels were normalized to β-actin as fold vs. 
controls. White bar, control (Ctrl); black bar, MIPβ1KO. Data are expressed as mean 
±SEM, *p < 0.05, vs. controls.  
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Figure 3.4: Efficiency of fetal beta-cell specific β1 integrin knockout with 1x or 3x 
tamoxifen dosage(s) between e13.5-15.5.  
(A) Representative double immunofluorescence images (top) and quantification (bottom) 
of β1 integrin+ beta-cells in MIPβ1KO and control mice with 1x tamoxifen dosage at 
e13.5 (n=7-8 pancreata per group). Scale bar: 25 µm. (B) Western blot densitometry for 
β1 integrin protein level in fetal MIPβ1KO and control mice treated with 3x tamoxifen 
dosage at e13.5-15.5 (n=3 pancreata per group). β1 integrin protein levels were 
normalized to β-actin and expressed as fold vs. controls. White bar, control; black bar,  
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3.3 Fetal MIPb1KO mice display smaller islets, loss of beta-
cell mass, and decreased beta-cell proliferation at e19.5.  
Immunofluorescence staining was performed on fetal pancreata to determine if 
the development of beta-cell mass was affected by the loss of β1 integrin in MIPβ1KO 
mice. The islet architecture was unchanged between control and MIPβ1KO groups, with 
clusters of insulin+ cells surrounded by glucagon+ cells observed in both fetal groups 
(Figure 3.5A). The morphometric analysis of islet density (islets per mm2) showed a 
significant reduction in MIPβ1KO pancreata when compared to controls (p < 0.05, Figure 
3.5B) The islet area (the combined glucagon+ & insulin+ area) was also significantly 
decreased in MIPβ1KO mice (p < 0.05 vs. controls, Figure 3.5C). The decrease in islet 
area was due to a significant reduction in both beta-cell area and mass in the MIPβ1KO 
mice, and not due to changes in the alpha-cell compartment of the islet (Figure 3.5F and 
G). The findings indicate that the knockout of β1 integrin in beta-cells affects the 
development of normal beta-cell mass with no impact on alpha-cell mass.  
To assess whether the loss of beta-cell mass is associated with beta-cell 
replication, the proliferation of beta-cells was examined using double 
immunofluorescence staining. A significant reduction of Ki67+/insulin+ cells was 
observed in the islets of MIPβ1KO pancreata when compared to controls (p < 0.05, 
Figure 3.6), indicating that normal β1 integrin signal is necessary for maintaining beta-
cell proliferation and adversely impacts the developing beta-cell mass. 
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Figure 3.5: Fetal MIPβ1KO mice display reduced beta-cell mass with unchanged 
alpha-cell mass at e19.5.  
(A) Representative double immunofluorescence images for glucagon (green) and insulin 
(red) staining in the islets of control and MIPβ1KO mice after 2x tamoxifen 
administration. Scale bar: 50µm. Nuclei labeled with DAPI (blue). (B) Islet density 
(islets/mm2), (C) percent islet area, (D) percent beta-cell area, (E) beta-cell mass, (F) 
percent alpha-cell area and (G) mass relative to whole pancreatic section area in control 
and MIPβ1KO mice (n=6 pancreata per group). White bar, control; black bar, MIPβ1KO. 
Data are expressed as means ± SEM. *p < 0.05, vs. controls. 
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Figure 3.6: Fetal MIPβ1KO mice show decreased beta-cell proliferation.  
 
(A) Representative double immunofluorescence images of Ki67+ (green) and insulin+ 
(red) cells in MIPβ1KO and control pancreatic sections with 2x tamoxifen administration. 
Nuclei labeled with DAPI (blue). White arrows indicate double positive cells. Scale bar: 
25 µm. (B) Quantification of Ki67+ beta-cells in MIPβ1KO and control islets (n=6 
pancreata per group). White bar, control; black bar, MIPβ1KO. Data are expressed as 
means ± SEM. *p < 0.05 vs. controls.  
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3.4 Fetal MIPb1KO pancreata displayed reduced Pdx-1 or 
insulin co-localization with ductal-cell marker. 
Pdx-1 is present in early developing pancreatic duct cells as a pancreatic 
progenitor cell and is also present in differentiated beta-cells as a key regulator for insulin 
gene expression (Du et al., 2009). To determine whether knockout of β1 integrin 
influences nascent Pdx-1+ cell populations in the ductal region and their migration into 
islet clusters, immunofluorescence staining for Pdx-1 with ductal marker pan-CK was 
evaluated (Figure 3.7A). The numbers of Pdx-1+/pan-CK+ cells in total Pdx-1+ cell 
clusters (p < 0.05, Figure 3.7B) and pan-CK+ ductal regions (p < 0.05, Figure 3.7C) were 
reduced in MIPβ1KO pancreas compared to controls. This suggests that the formation of 
pancreatic progenitor Pdx-1+ cells near the ductal region are impacted by β1 integrin loss.   
Insulin+ co-staining with pan-CK+ cells was also assessed to confirm that the 
emerging Pdx-1+ cells were beta-cells and not another population of islet endocrine cells. 
Similar results were observed with the co-localization of insulin+/pan-CK+ beta-cells in 
MIPβ1KO ductal and islet clusters (p < 0.05, Figure 3.8A and B). This data further 
verified that the loss of β1 integrin in the developing pancreas could impair potential 
beta-cell differentiation from Pdx-1+ cells and reduce the formation of new beta-cells 
along with their migration into the islet clusters. 
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Figure 3.7: Characterization of co-stained Pdx-1 and pan-CK cells in the islet and 
ductal cells of fetal MIPβ1KO mice after 2x tamoxifen administration.  
(A) Representative double immunofluorescence images of ductal cell marker pan-CK 
(green) and pancreatic progenitor Pdx-1 (red) cells. White arrows indicate Pdx-1 nuclear 
localization in pan-CK+ ductal cells. Scale bar: 25 µm. (B) Quantification of Pdx-1+/pan-
CK+ cells in total Pdx-1+ cells. (C) Quantification of Pdx-1+/pan-CK+ cells in total pan-
CK+ cells. White bar, control; black bar, MIPβ1KO. Data are expressed as means ± SEM 
(n = 4 pancreata per group). *p < 0.05, vs. controls. 
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Figure 3.8: Characterization of insulin and pan-CK co-localized cells in the islet and 
ductal cells of fetal MIPβ1KO mice after 2x tamoxifen administration.  
(A) Representative double immunofluorescence images of pan-CK (green) and insulin 
(red). White arrows indicate insulin co-staining with pan-CK. Scale bar: 25 µm. (B) 
Quantification of insulin+/pan-CK+ cells in total insulin+ cells. (C) Quantification of 
insulin+/pan-CK+ cells in total pan-CK+ cells. White bar, control; black bar, MIPβ1KO. 
Data are expressed as means ± SEM (n = 4 pancreata per group). *p < 0.05, vs. controls. 
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3.5 Fetal MIPb1KO islets expressed transcription factors 
necessary for beta-cell identity. 
Morphological and proliferative changes in the MIPβ1KO pancreas may signify 
potential changes to transcription factors that are important for the development and 
function of beta-cells. The effects of β1 integrin loss on beta-cell identity during pancreas 
development were determined using immunofluorescence and immunohistochemistry 
staining approaches. 
Qualitative comparison of control and MIPβ1KO pancreatic sections revealed that both 
groups had similar levels of nuclear TFs Pdx-1, Nkx6.1 and Isl-1 in insulin+ cells (Figure 
3.9). Nuclear staining for MafA also showed similar expression in both pancreatic 
sections (Figure 3.9). These staining data indicate that beta-cell identity is maintained 
throughout the second transition stage of pancreas growth despite the loss of β1 integrin. 
Glucose transporter 2 (Glut-2) is the major glucose transporter in mouse beta-cells 
and is required for glucose uptake and glucose-stimulated insulin secretion (GSIS) in 
both adult and neonatal pancreata (Sansbury et al., 2012; Thorens et al., 1992). The 
expression of Glut-2 in insulin+ cells was similar in intensity between control and 
MIPβ1KO islets, although MIPβ1KO islets were smaller (Figure 3.10A).  Since beta-cell 
specific β1 integrin knockout does not change beta-cell identity, the delta (somastostatin) 
and gamma (pancreatic polypeptide) cells were assessed in fetal islets to determine if 
other endocrine cell fates were affected. Qualitative immunofluorescence analysis also 
confirmed that control and MIPβ1KO islets contained similar level of both endocrine cell 
populations within islet clusters (Figure 3.10B and C).   
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Figure 3.9: Fetal MIPβ1KO islets expressed transcription factors necessary for beta-
cell identity.  
Representative double immunofluorescence images showing that insulin+ cells (red) of 
both MIPβ1KO and control pancreata display nuclear localization of transcription 
markers (A) Pdx-1, (B) Nkx6.1, and (C) Islet-1 (green) after 2x tamoxifen administration. 
DAPI, blue. (D) Immunohistochemical staining demonstrates similar levels of MafA 
(red) in both experimental groups. Nuclei were labeled with hematoxylin (purple). Scale 
bar: 25 µm. (n=3 pancreata per group) 
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Figure 3.10: Fetal MIPβ1KO islets displayed endocrine cell identity.  
Representative double immunofluorescence images showing (A) Glut 2, (B) 
Somatostatin, and (C) pancreatic polypeptide (green) with beta-cell staining (Insulin, red) 
for endocrine identity of both MIPβ1KO and control pancreata after 2x tamoxifen 
administration. DAPI, blue. Staining demonstrates similar levels in both experimental 
groups (n=3 pancreata per group). Scale bar: 25 µm 
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3.6 Fetal MIPb1KO mice displayed decreased 
vascularization 
Islet vasculature is required for normal islet growth and function. Maintenance of 
the islet vascular endothelial cell population is essential for the formation of the basement 
membrane in close proximity to beta-cells, which contributes to their proliferation and 
function through β1 integrin - laminin activation (Nikolova et al., 2006). To assess 
whether loss of beta-cell β1 integrin affected the contribution of islet vascularization to 
beta-cell mass, morphological analysis of islet vascularization with double 
immunostaining for PECAM-1+ and insulin+ was used to determine the islet capillary 
area and density (Figure 3.11A). MIPβ1KO pancreas sections displayed a lower area of 
islet vascularization (islet capillary area in total islet area) compared to controls (p < 
0.05, Figure 3.11B). The density of capillaries in MIPβ1KO islets was also reduced (p < 
0.05, Figure 3.11C). These findings are consistent with the concept that the islet 
microvasculature may affect beta-cell proliferation and supports the interaction between 
the ECM, endothelial cells, and beta-cells via β1 integrin in promoting beta-cell mass. 
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Figure 3.11: Fetal MIPβ1KO pancreata displayed decreased vascularization. 
(A) Representative co-immunofluorescence images show decreased vascularization 
(PECAM-1, green) in the pancreatic islets (Insulin, red) of MIPβ1KO and control mice 
after 2x tamoxifen administration. White arrows indicate PECAM-1+ cells. Scale bar: 25 
µm. Quantification of immunofluorescence images for (B) the percent of PECAM-1+ area 
over total islet area and (C) islet vessel density (n = 4-5 pancreata per group). White bars, 
control; black bars, MIPβ1KO. Data are expressed as means ± SEM. *p < 0.05 vs. 
controls.  
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3.7 Downstream b1 integrin signaling in the MIPb1KO 
pancreas 
Since decreased beta-cell mass and proliferation were observed in fetal MIPβ1KO 
mice, downstream β1 integrin signalling pathways involved in cell proliferation were 
investigated. Western blot analysis displayed a downregulation of ERK1/2 signalling 
indicated by a decrease in phosphorylated ERK1/2 (p<0.05 vs. controls, Figure 3.12A). 
Akt is also a part of the integrin downstream signalling cascade and plays a role in beta-
cell survival. However, same for signaling mark phosphorylated AktS473 levels were 
unchanged in MIPβ1KO pancreata when compared to controls (Figure 3.12B). Akt 
activation has been shown to decrease apoptosis by inhibiting downstream p53 activation. 
Correlating with unchanged phosphorylated Akt levels, phosphorylated p53 levels were 
also similar in levels between MIPβ1KO and control pancreata (Figure 3.12C). Apoptotic 
activity marked by cleaved caspase-3 level were also not altered (Figure 3.12D). Taken 
together, intracellular signaling pathways in MIPβ1KO beta-cells indicate reduced 
proliferation and neogenesis with unchanged levels of apoptotic activity.  
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Figure 3.12: Downstream β1 integrin signaling pathway analysis.  
Western blot analyses for (A) phospho- and total-ErkT202/Y204, (B) phospho- and total-
AktS473, (C) phospho- and total-p53Ser15 and (D) cleaved and total caspase-3 (n = 4 
pancreata per group) in fetal control and MIPβ1KO pancreata after 2x tamoxifen 
administration. Representative blotting images are shown. White bars, control; black 
bars, MIPβ1KO. Data are normalized to control and expressed as means ± SEM. *p < 
0.05.  
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Chapter 4 - Discussion 
This study examined the in vivo role of beta-cell β1 integrin in pancreatic 
endocrine cell development using a temporally tamoxifen-induced MIPβKO mouse 
model. Compared to other β1 integrin KO studies that utilized the Cre recombinase 
system in congenital RIPβ1KO and adult MIPβ1KO models, this project focuses on the 
loss of β1 integrin at the beginning of the second transition stage of embryonic pancreas 
growth. MIPβ1KO fetal pancreata demonstrated a decrease in beta-cell mass, 
proliferation, ERK signaling, and islet vascularization. In addition, formation of nascent 
and new beta-cells in the ductal region were impaired in MIPβ1KO fetal pancreas. 
However, key TF expression required for normal islet development was not affected. 
Taken together, this study suggests that beta-cell β1 integrin is required for expanding 
beta-cell growth during their differentiation and maturation in the second stage of 
pancreatic development. 
4.1 Frequency of tamoxifen administration on the degree of 
β1 integrin knockout in MIPβ1KO beta-cells. 
The specificity of Cre recombinase activity within beta-cells of MIPCreERT mice 
was verified in our lab previously by crossing the mouse line with B6.Cg-
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J reporter mice (Trinder et al., 2016). An initial 
tamoxifen dosage of 6 mg/ 40 g bodyweight was given for a single day at e13.5 to induce 
knockout in MIPβ1KO fetal mouse. This method was adapted from Trinder et al. (2016), 
where 75% of insulin receptor knockout was observed through western blot. This study 
examined the oral gavage route instead of the single intraperitoneal (I.P.) used in 
pregnant dams from Trinder et al. (2016), and knockdown efficiency with this route was 
assessed using different dosages. Oral gavage was selected over I.P. injection due to the 
higher toxic effect on the pregnant dam observed with earlier I.P. injection experiments. 
1x tamoxifen dosage at e13.5 only induced a 20% loss in beta-cell β1 integrin when 
compared to the 2x dosage at e13.5 and e15.5 (56% knockout). This level of β1 integrin 
knockout was similar to the knockout achieved in I.P. –administered postnatal MIPβ1KO 
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(60% knockout) (Peart et al., 2017). This suggests that both routes of tamoxifen 
administration are an acceptable form of inducing β1 integrin knockout in the beta-cell 
target, but the dosage frequency received for successful in utero recombination is 
dependent on the administration route used where in our study, the oral gavage route 
required a higher dosage frequency.  
Administering the 3x tamoxifen dosage from e13.5 to e15.5 produced a 50% loss 
in beta-cell β1 integrin. Consecutive administration of high tamoxifen concentrations was 
shown to produce adverse effects during pregnancy as higher instances of premature birth 
and intrauterine fetus death were observed. A higher proportion of abnormal birth 
observed with the 3x tamoxifen dosage was not specific to the MIPβ1KO genotype, 
suggesting that irregular fetus growth was due to the adverse effects from tamoxifen and 
not due to beta-cell β1 integrin knockout. This may indicate a dose-dependent toxicity 
effect with tamoxifen administration similar to previous  reports that utilize tamoxifen 
(Bersell et al., 2013; Denk et al., 2015). Considering the efficiency of β1 integrin 
knockout between the three tamoxifen dosages and the toxicity effect on fetuses, the 2x 
tamoxifen dosage was demonstrated to be the most appropriate dosage for our study and 
was selected for all subsequent studies.    
4.2 Beta-cell specific β1 integrin knockout on beta-cell mass 
and proliferation. 
Even with similar body and pancreas weight between MIPβ1KO and littermate 
controls, quantitative analysis of islet morphology showed a significant reduction in beta-
cell mass and area, as well as total islet area, for MIPβ1KO fetuses by the end of the 
second transition stage. This is similar to previous studies with congenital beta-cell β1 
integrin knockout using RIP-driven Cre recombinase (Diaferia et al., 2013) or when 
knockout was induced in 4-week old MIPβ1KO adult mice (Peart et al., 2017). Along 
with the decrease in beta-cell mass, overall islet density was reduced in the MIPβ1KO 
pancreas, which was also found in earlier studies (Diaferia et al., 2013; Peart et al., 2017). 
Since the MIPβ1KO alpha-cell mass and area were unaffected, the loss of overall islet 
area was likely due to the significant reduction in beta-cell area and mass. This was also 
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consistent with adult MIPβ1KO study with unchanged alpha-cell and a reduction in beta-
cell area (Peart et al., 2017). Adult male mice with a global knockout of β1 integrin in 
collagen-producing Col1a2 cells, a major ligand in ECM-β1 integrin interaction, 
demonstrated a decrease in beta-cell mass (Riopel et al., 2011). β1 integrin activates the 
MAPK/ERK pathway through association with FAK to regulate beta-cell, furthermore, 
ablation of FAK in beta cells showed a similar reduction in beta-cell mass (Cai et al., 
2012; Saleem et al., 2009).  These results emphasize that β1 integrin expression is 
required throughout pre- and postnatal development to maintain beta-cell mass. Since the 
second transition stage is largely characterized by beta-cell differentiation and expansion 
(Gunasekaran et al., 2012; Habener et al., 2005; Kaung, 1994), the loss of beta-cell β1 
integrin during this stage is expected to cause a defect in beta-cell growth. Our data 
verified that the loss of b1 integrin from e13.5 led to a reduction of beta-cell mass at 
e19.5 in MIPb1KO pancreas, indicating a sensitive in vivo time window during 
development that is essential for beta-cell growth. These findings implicate that beta-cell 
b1 integrin is important for normal beta-cell mass development during the second 
transition stage of pancreas growth.   
Cell cycle progression and signaling in MIPβ1KO beta-cells were examined to 
determine its contribution to reduced islet density, beta-cell mass, and area. The 
FAK/MAPK/ERK signaling cascade has been shown to be activated through β1 integrin 
to maintain beta-cell function and growth in vitro (Hammar et al., 2004; Saleem et al., 
2009; Wang et al., 2005) and in vivo models (Cai et al., 2012; Peart et al., 2017; Riopel et 
al., 2011). A decrease in beta-cell proliferation and phosphorylation of downstream 
signaling molecule ERK1/2 were found in MIPβ1KO fetal pancreata, which is also 
similar with previous adult β1KO, MIPβ1KO and congenital RIPβ1KO beta-cell studies 
(Diaferia et al., 2013; Peart et al., 2017; Riopel et al., 2013).  The impairment in ERK1/2 
signaling in MIPβ1KO fetuses during the second transition stage could contribute to 
decreased beta-cell proliferation and expansion. 
β1 integrin deficiency has also been shown to play a role in the survival of beta-
cells through PI3K and downstream phosphorylation of AktS473 protein, which regulates 
anti-apoptotic p53 and pro-apoptotic cleaved caspase-3 protein signaling (Diaferia et al., 
67 
 
2013; Peart et al., 2017; Xia et al., 2004). However, western blot analysis in the 
MIPβ1KO fetal pancreas did not show a change in phospho-Akt, phospho-p53 or cleaved 
caspase-3 activity in the fetal MIPβ1KO pancreas. The unchanged levels of phospho-Akt, 
cleaved caspase-3, and phopho-p53 proteins may suggest that β1 integrin signaling 
during the second transition stage does not influence cell survival through the Akt 
pathway.  
Although adult MIPb1KO islets displayed a down-regulation of Akt 
phosphorylation with change of cyclin D1 and cleaved PARP (Peart et al., 2017),  adult 
β1KO mice and β1 integrin blockade in INS-1 studies showed a similar reduction in 
phospho-ERK with no change to the Akt phosphorylation (Krishnamurthy et al., 2011; 
Riopel et al., 2011). Furthermore, blocking b1 integrin in the human fetal pancreatic cells 
also showed down-regulation of ERK pathway with no change in the Akt signaling 
pathway (Wang et al, 2005, Saleem et al., 2009). Taken together, our current and 
previous in vivo and in vitro studies suggest that β1 integrin signals primarily through the 
MAPK/ERK pathway, with no effect on Akt pathway during the second transition stage 
of embryonic pancreas development.  
4.3 Newly formed beta-cell from the ductal compartment in 
MIPβ1KO mice. 
Since pancreatic progenitor cells in the ductal epithelium undergo a process of 
cell budding, migration, and differentiation to form islet cells clusters during the second 
transition stage (Alpert et al., 1988; Gu & Sarvetnick, 1993), MIPβ1KO pancreata were 
examined to determine if beta-cell formation in the pancreatic ductal region was also 
affected and contributed to the reduced beta-cell mass. Decreased number of Pdx-1+ or 
insulin+ ductal cells in both ductal and islet cluster region of fetal MIPβ1KO pancreata 
were observed through immunofluorescence staining, indicating that beta-cell β1 integrin 
knockout also impaired nascent beta-cells in the pancreatic ductal region. Previously, 
aVβ1 integrin expression has been shown as a requirement for fetal pancreatic beta-cell 
spreading and migration during islet neogenesis (Kaido et al., 2010). This may indicate 
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that beta-cell knockout of β1 integrin impaired the formation of both pancreatic 
progenitor (Pdx-1+) and beta-cells (insulin+) in the ductal epithelium.    
In addition, integrin-matrix interactions for αvβ5 and αvβ3 through vitronectin 
and fibronectin has been shown to be required for emerging islet cells from fetal ductal 
epithelium (Cirulli et al., 2000) , and both vitronectin and fibronectin are major β1 
integrin-ECM associated ligands. Therefore, a possible reduction in beta-cell β1 integrin 
interaction with these key associated ligands in the MIPβ1KO may have affected the 
differentiation or emergence of Pdx-1+ and insulin+ cells in the ductal epithelium. These 
results may suggest that reduced beta-cell mass in fetal MIPβ1KO pancreata is due to a 
combination of decreased beta-cell proliferation and formation of nascent endocrine cell 
in the ductal compartment during the second transition stage.  
4.4 Endocrine and beta-cell specific transcription factors in 
MIPβ1KO mice. 
We examined if fetal MIPβ1KO beta-cells had altered expression of TFs 
necessary for proper beta-cell development. Pdx-1 is an important TF that maintains beta-
cell identity, growth, and survival (Brissova et al., 2006; Gittes, 2009; Offield et al., 
1996). Previous Pdx-1 gene mutation studies have shown hindered pancreatic 
development and a loss of differentiation in pancreatic progenitors and beta-cells (Guo et 
al., 2013; Jonsson et al., 1994; Offield et al., 1996). A decrease in beta-cell Pdx-1 was 
also observed in the adult β1KO studies with postnatal β1 integrin knockout (Peart et al., 
2017; Riopel et al., 2011). Since adult β1KO mice displayed a decrease in insulin content 
and glucose intolerance, reduced beta-cell Pdx-1 expression is more likely to be 
associated with its role for insulin synthesis and glucose metabolism in the mature β1KO 
pancreas. However, qualitative assessment of Pdx-1 appears to be unchanged in fetal 
MIPβ1KO beta-cells, which is similar to the findings from congenital RIPβ1KO mice 
(Diaferia et al., 2013). Even with the observed reduction of Pdx-1+ cells in the ductal 
region, unchanged MIPβ1KO Pdx-1 expression in the beta-cell may suggest that β1 
integrin knockout does not affect beta-cell identity once the islet cluster is formed during 
the second transition stage of pancreatic growth. Expression of TFs MafA, Islet-1, and 
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Nkx6.1 are also required during development for beta-cell maturation (Aguayo-
Mazzucato et al., 2013; Bonner-Weir et al., 2016; Sander et al., 2000). Our study showed 
no change in nuclear expression of these transcription factors between fetal MIPβ1KO 
and the control islets, which was similar to the congenital RIPβ1KO study (Diaferia et al., 
2013). This may also suggest that beta-cell β1 integrin knockout did not affect the 
expression of other major TFs needed for beta-cell development during the second 
transition stage.  
4.5 Islet vascularization in MIPβ1KO mice. 
Islet vascularization is important for maintaining beta-cell function (Brissova et 
al., 2006; Lammert et al., 2003). The angiogenic promoting factor, Vegf, is secreted by 
beta-cell and attracts vascular endothelial cell formation close to the endocrine clusters 
(Inoue et al., 2002; Lecouter et al., 2001; Watada, 2010). Laminin in the basement 
membrane of nearby endothelial cells has been found to interact with beta-cell β1 integrin 
and promote beta-cell proliferation and insulin expression (Nikolova et al., 2006).  Our 
study showed a significant decrease in islet vessel density and islet capillary area in fetal 
MIPβ1KO islets. This is consistent to the Riopel et al. (2011) β1KO study where a 
similar reduction in adult islet capillary area was observed. During the second transition 
stage of pancreas development, reduced beta-cells mass in MIPβ1KO mice may have 
impaired Vegf production, leading to reduced nearby endothelial cell formation and 
overall islet vascularization (Nikolova et al., 2006). This result may further provide 
support that β1 integrin is required for islet vascularization in fetal MIPβ1KO pancreata 
during the second transition stage of pancreas development.  
4.6 Limitation of this study  
Fetal MIPβ1KO during the second transition stage of pancreas development 
currently shows a significant decrease in islet vascularization. However, determining 
potential changes in Vegf-a of MIPβ1KO beta-cells was unsuccessful due to the quality 
of isolation which appeared to be protein specific. A similar issue was encountered with 
assessing phosphorylated-FAK levels, which would have contributed towards 
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understanding the FAK/MAPK/ERK pathway during this stage of development. Our 
study showed a reduction in nascent beta-cell population in the ductal and islet clusters, 
however, the reason for this impairment was not fully determined to be from the 
migration and/or immediate cell death of the newly formed beta-cells. Unfortunately, 
there was also a significant difficulty in obtaining a larger fetal pancreas sample which 
may have potentially skewed the data.   
 Studies that focused on the postnatal development of MIPβ1KO mice was 
attempted to determine if the loss of beta-cell β1 integrin during the second transition 
stage affected beta-cell remodeling and function in the adult mice. However, tamoxifen 
administration to pregnant dams led to either infanticide or neglect towards the newborn 
litters. Tamoxifen and/or handling during the gestational period may have caused an 
adverse effect on pregnant mothers’ behaviour and health. Cross-fostering with 
tamoxifen-free mothers has been implemented but has also demonstrated minimal 
success due to persistent litter neglect.  
4.7 Conclusion and future direction  
This study demonstrated the temporal role of beta-cell b1 integrin during the 
second transition stage of murine pancreas development. MIPb1KO mice had a reduction 
in beta-cell mass and area. Loss in MIPb1KO beta-cells was due to decreased beta-cell 
proliferation, ERK signalling, and formation of nascent Pdx-1+ cells and beta-cells from 
the ductal epithelium, with an overall reduction in intraislet vascularization. This study 
may improve our understanding of b1 integrin role in beta-cell differentiation during the 
critical pancreatic developmental window.  
Since our study only displayed a decrease in emerging Pdx-1+ and insulin+ beta-cell in 
the ductal region, real-time migration of these nascent beta cells was not investigated. 
Utilizing in vivo time-based microscopy with fluorescent labelling to mark nascent beta-
cell movement towards islet clusters would determine migration defects in MIPb1KO 
mice during the second transition stage of pancreas morphogenesis. 
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MIPb1KO mice displayed decreased islet blood vessel formation during the second 
transition stage of pancreas development. Since proper vascularization is required for 
pancreas growth (Lammert et al., 2001; 2003; Magenheim et al., 2011), investigating 
MIPb1KO beta-cell Vegf and islet endothelial laminin expression could build on the 
working model for b1 integrin-vasculature interaction during beta-cell growth (Nikolova 
et al., 2006).     
Formation of new fetal and neonatal beta-cells during the third transition stage is largely 
from neogenesis, while new adult beta-cells are produced through replication (Scaglia et 
al., 1997). b1 integrin knockout at the beginning of the second transition stage of 
pancreas development showed decreased beta-cell mass by the end of this stage. Further 
examining the pancreatic growth of these mice throughout the neonatal and postnatal 
stages would allow us to determine if islet morphological changes due to b1 integrin 
knockout at the second stage of transition impairs adult beta-cell function. This study has 
shown that beta-cell b1 integrin is important during the second transition stage of 
pancreas development which may provide future direction towards beta-cell cell 
adhesion’s role in pancreas growth.  
 
72 
 
Chapter 5 - References 
Afelik, S., & Jensen, J. (2013). Notch signaling in the pancreas: Patterning and cell fate 
specification. Wiley Interdisciplinary Reviews: Developmental Biology, 2(4), 531–544.  
Aguayo-Mazzucato, C., Zavacki, A. M., Marinelarena, A., Hollister-Lock, J., El 
Khattabi, I., Marsili, A., Bonner-Weir, S. (2013). Thyroid hormone promotes postnatal 
rat pancreatic β-cell development and glucose-responsive insulin secretion through 
MAFA. Diabetes, 62(5), 1569–1580. 
Ahlgren, U., Pfaff, S. L., Jessell, T. M., Edlund, T., & Edlund, H. (1997). Independent 
requirement for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature. 385, 
257-260 
Alpert, S., Hanahan, D., & Teitelman, G. (1988). Hybrid insulin genes reveal a 
developmental lineage for pancreatic endocrine cells and imply a relationship with 
neurons. Cell, 53(2), 295–308. 
Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A., & Wollheim, C. B. (1992). 
Establishment Differentiated of 2-Mercaptoethanol-Dependent Insulin-Secreting Cell 
Lines. Endocrinology, 130(1), 167–178.  
Barczyk, M., Carracedo, S., & Gullberg, D. (2010). Integrins. Cell and Tissue Research, 
339(1), 269–280.  
Bersell, K., Choudhury, S., Mollova, M., Polizzotti, B. D., Ganapathy, B., Walsh, S., 
Kuhn, B. (2013). Moderate and high amounts of tamoxifen in MHC-MerCreMer mice 
induce a DNA damage response, leading to heart failure and death. Disease Models & 
Mechanisms, 6(6), 1459–1469. 
Bonner-Weir, S., Aguayo-Mazzucato, C., & Weir, G. C. (2016). Dynamic development 
of the pancreas from birth to adulthood. Upsala Journal of Medical Sciences, 121(2), 
155–158.  
Boudreau, N. J., & Jones, P. L. (1999). Extracellular matrix and integrin signaling: the 
shape of things to come. The Biochemical Journal, 339 (3), 481–488.  
Bouvard, D., Brakebusch, C., Gustafsson, E., Aszódi, A., Bengtsson, T., Berna, A., & 
Fässler, R. (2001). Functional consequences of integrin gene mutations in mice. 
Circulation Research, 89(3), 211–223.  
73 
 
Brissova, M., Shostak, A., Shiota, M., Wiebe, P. O., Poffenberger, G., Kantz, J., Powers, 
A. C. (2006). Pancreatic islet production of vascular endothelial growth factor-A is 
essential for islet vascularization, revascularization, and function. Diabetes, 55(11), 
2974–2985. 
Burlison, J. S., Long, Q., Fujitani, Y., Wright, C. V. E., & Magnuson, M. A. (2009). Pdx-
1 and Ptf1a concurrently determine fate specification of pancreatic multipotent progenitor 
cells. Molecular Physiology, 316(1), 74–86.  
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. 
(2006). The unique cytoarchitecture of human pancreatic islets has implications for islet 
cell function. Proceedings of the National Academy of Sciences, 103(7), 2334–2339.  
Cai, E. P., Casimir, M., Schroer, S. A., Luk, C. T., Shi, S. Y., Choi, D., Woo, M. (2012). 
In vivo role of focal adhesion kinase in regulating pancreatic β-cell mass and function 
through insulin signaling, actin dynamics, and granule trafficking. Diabetes, 61(7), 1708–
1718.  
Christofori, G., Naik, P., & Hanahan, D. (1995). Vascular endothelial growth factor and 
its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet 
cell tumourigenesis. Mol. Endocrinol., 9(12), 1760–1770.   
Cirulli, V., Beattie, G. M., Klier, G., Ellisman, M., Ricordi, C., Quaranta, V., Salomon, 
D. R. (2000). Expression and Function of αvβ3 and αvβ5 Integrins in the Developing 
Pancreas. The Journal of Cell Biology, 150(6), 1445–1460.  
Collombat, P., Mansouri, A., Hecksher-sørensen, J., Serup, P., Krull, J., Gradwohl, G., & 
Gruss, P. (2003). Opposing actions of Arx and Pax4 in endocrine pancreas development 
Opposing actions of Arx and Pax4 in endocrine pancreas development, 4(17), 2591–
2603.  
Collombat, P., Xu, X., Ravassard, P., Sosa-Pineda, B., Dussaud, S., Billestrup, N., 
Mansouri, A. (2009). The Ectopic Expression of Pax4 in the Mouse Pancreas Converts 
Progenitor Cells into α and subsequently β Cells. Cell, 138(3), 449–462.  
Cordes, N., Seidler, J., Durzok, R., Geinitz, H., & Brakebusch, C. (2006). Β1-Integrin-
Mediated Signaling Essentially Contributes To Cell Survival After Radiation-Induced 
Genotoxic Injury. Oncogene, 25(9), 1378–1390. 
Denk, F., Ramer, L. M., Erskine, E. L. K. S., Nassar, M. A., Bogdanov, Y., Signore, M., 
Ramer, M. S. (2015). Tamoxifen induces cellular stress in the nervous system by 
74 
 
inhibiting cholesterol synthesis. Acta Neuropathologica Communications, 3, 74.  
Diaferia, G. R., Jimenez-Caliani, A. J., Ranjitkar, P., Yang, W., Hardiman, G., Rhodes, 
C. J., Cirulli, V. (2013). β1 integrin is a crucial regulator of pancreatic -cell expansion. 
Development, 140(16), 3360–3372. 
Dor, Y., Brown, J., Martinez, O. I., & Melton, D. A. (2004). Adult pancreatic β-cells are 
formed by self-duplication rather than stem-cell differentiation. Nature, 429(6987), 41–
46.  
Du, A., Hunter, C. S., Murray, J., Noble, D., Cai, C., Evans, S. M., May, C. L. (2009). 
Survival of the Endocrine Pancreas. Diabetes, 58(September), 2059–2069.  
Fassler, R., & Brakebusch, C. (2005). β1 integrin function in vivo: Adhesion, migration 
and more. Cancer and Metastasis Reviews, 403–411.  
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010). The extracellular matrix at a glance. 
Journal of Cell Science, 123(24), 4195–4200. 
Gahmberg, C. G., Fagerholm, S. C., Nurmi, S. M., Chavakis, T., Marchesan, S., & 
Grönholm, M. (2010). Regulation of integrin activity and signaling. Biochim Biophys 
Acta., 1790(6), 431–444.  
Gittes, G. K. (2009). Developmental biology of the pancreas: A comprehensive review. 
Developmental Biology 326, 4-35. 
Gradwohl, G., Dierich, A., LeMeur, M., & Guillemot, F. (2000). Neurogenin3 is required 
for the development of the four endocrine cell lineages of the pancreas. Proceedings of 
the National Academy of Sciences, 97(4), 1607–1611.  
Gu, D., & Sarvetnick, N. (1993). Epithelial cell proliferation and islet neogenesis in IFN-
g transgenic mice. Development, 118, 33–46. 
Gu, G., Dubauskaite, J., & Melton, D. A. (2002). Direct evidence for the pancreatic 
lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. 
Development, 129(10), 2447–2457.  
Gunasekaran, U., Hudgens, C. W., Wright, B. T., Maulis, M. F., & Gannon, M. (2012). 
Differential regulation of embryonic and adult β cell replication. Cell Cycle, 11(13), 
2431–42.  
Guo, L., Inada, A., Aguayo-Mazzucato, C., Hollister-Lock, J., Fujitani, Y., Weir, G. C. 
75 
 
Bonner-Weir, S. (2013). PDX1 in ducts is not required for postnatal formation of β-cells 
but is necessary for their subsequent maturation. Diabetes, 62(10), 3459–3468.  
Habener, J. F., Kemp, D. M., & Thomas, M. K. (2005). Minireview: Transcriptional 
Regulation in Pancreatic Development. Endocrinology, 146(3), 1025–1034.  
Hald, J., Sprinkel, A. E., Ray, M., Serup, P., Wright, C., & Madsen, O. D. (2008). 
Generation and characterization of Ptf1a antiserum and localization of Ptf1a in relation to 
Nkx6.1 and Pdx1 during the earliest stages of mouse pancreas development. Journal of 
Histochemistry and Cytochemistry, 56(6), 587–595.  
Halvorsen, T. L., Beattie, G. M., Lopez, A. D., Hayek, A., & Levine, F. (2000). 
Accelerated telomere shortening and senescence in human pancreatic islet cells 
stimulated to divide in vitro. Journal of Endocrinology, 166(1), 103–109. 
Hammar, E., Parnaud, G., Bosco, D., Perriraz, N., Maedler, K., Donath, M., Halban, P. 
A. (2004). Extracellular matrix protects pancreatic β-cells against apoptosis: Role of 
short- and long-term signaling pathways. Diabetes, 53(8), 2034–2041.  
Harris, E. S., McIntyre, T. M., Prescott, S. M., & Zimmerman, G. A. (2000). The 
leukocyte integrins. Journal of Biological Chemistry, 275(31), 23409–23412.  
Henderson, J. R., & Moss, M. C. (1985). A Morphometric Study of the Endocrine and 
Exocrine Capillaries of the Pancreas. Quarterly Journal of Experimental Physiology, 
70(3), 347–356. 
Hill, D. J. (2005). Development of the endocrine pancreas. Reviews in Endocrine and 
Metabolic Disorders, 6(3), 229–238.  
Inoue, M., Hager, J. H., Ferrara, N., Gerber, H. P., & Hanahan, D. (2002). VEGF-A has a 
critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. 
Cancer Cell, 1(2), 193–202.  
Jacquemin, P., Lemaigre, F. P., & Rousseau, G. G. (2003). The Onecut transcription 
factor HNF-6 (OC-1) is required for timely specification of the pancreas and acts 
upstream of Pdx-1 in the specification cascade. Developmental Biology, 258(1), 105–116.  
James Shapiro, A. M. (2012). Islet transplantation in type 1 diabetes: Ongoing 
challenges, refined procedures, and long-term outcome. Review of Diabetic Studies, 9(4), 
385–406. 
Jansson, L., & Hellerström, C. (1983). Stimulation by glucose of the blood flow to the 
76 
 
pancreatic islets of the rat. Diabetologia, 25(1), 45–50.  
Jiang, F. X., Mehta, M., & Morahan, G. (2010). Quantification of insulin gene expression 
during development of pancreatic islet cells. Pancreas, 39(2), 201–8.  
Johansson, K. A., Dursun, U., Jordan, N., Gu, G., Beermann, F., Gradwohl, G., & 
Grapin-Botton, A. (2007). Temporal Control of Neurogenin3 Activity in Pancreas 
Progenitors Reveals Competence Windows for the Generation of Different Endocrine 
Cell Types. Developmental Cell, 12(3), 457–465.  
Jonathan D. Humphries, Adam Byron, and M. J. H. (2006). Journal of Cell Science 
Integrin ligands at a glance. J Cell Sci., 119(19), 3901–3903.  
Jonsson, J., Carlsson, L., Edlund, T., & Edlund, H. (1994). Insulin-promoter-factor 1 is 
required for pancreas development in mice. Nature, 371(6498), 606-609. 
Jørgensen, M. C., Ahnfelt-Rønne, J., Hald, J., Madsen, O. D., Serup, P., & Hecksher-
Sørensen, J. (2007). An illustrated review of early pancreas development in the mouse. 
Endocrine Reviews, 28(6), 685–705.  
Kaido, T. J., Yebra, M., Kaneto, H., Cirulli, V., Hayek, A., & Montgomery, A. M. P. 
(2010). Impact of integrin-matrix interaction and signaling on insulin gene expression 
and the mesenchymal transition of human β-cells. Journal of Cellular Physiology, 224(1), 
101–111. 
Kaido, T., Perez, B., Yebra, M., Hill, J., Cirulli, V., Hayek, A., & Montgomery, A. M. 
(2004). αv-Integrin Utilization in Human β-Cell Adhesion, Spreading, and Motility. 
Journal of Biological Chemistry, 279(17), 17731–17737.  
Kantengwa, S., Baetens, D., Sadoul, K., Buck, C. a, Halban, P. a, & Rouiller, D. G. 
(1997). Identification and characterization of alpha 3 beta 1 integrin on primary and 
transformed rat islet cells. Experimental Cell Research, 237(2), 394–402.  
Kaung, H. L. (1994). Growth dynamics of pancreatic islet cell populations during fetal 
and neonatal development of the rat. Developmental Dynamics : An Official Publication 
of the American Association of Anatomists, 200(2), 163–175.  
Kawaguchi, Y., Cooper, B., Gannon, M., Ray, M., MacDonald, R. J., & Wright, C. V. E. 
(2002). The role of the transcriptional regulator Ptf1a in converting intestinal to 
pancreatic progenitors. Nature Genetics, 32(1), 128–134.  
Kesavan, G., Sand, F. W., Greiner, T. U., Johansson, J. K., Kobberup, S., Wu, X., Semb, 
77 
 
H. (2009). Cdc42-Mediated Tubulogenesis Controls Cell Specification. Cell, 139(4), 
791–801. 
Kitamura, T., Kitamura, Y. I., Kobayashi, M., Kikuchi, O., Sasaki, T., DePinho, R. A., & 
Accili, D. (2009). Regulation of Pancreatic Juxtaductal Endocrine Cell Formation by 
FoxO1. Molecular and Cellular Biology, 29(16), 4417–4430.  
Kopinke, D., Brailsford, M., Shea, J. E., Leavitt, R., Scaife, C. L., & Murtaugh, L. C. 
(2011). Lineage tracing reveals the dynamic contribution of Hes1+ cells to the developing 
and adult pancreas. Development, 138(3), 431–441.  
Krishnamurthy, M., Li, J., Al-Masri, M., & Wang, R. (2008). Expression and function of 
αβ1 integrins in pancretic beta (INS-1) cells. Journal of Cell Communication and 
Signaling, 2(3), 67–79. 
Krishnamurthy, M., Li, J., Fellows, G. F., Rosenberg, L., Goodyer, C. G., & Wang, R. 
(2011). Integrin α3, but not β1, regulates islet cell survival and function via PI3K/Akt 
signaling pathways. Endocrinology, 152(2), 424–435 
Lammert, E., Cleaver, O., & Melton, D. (2001). Induction of pancreatic differentiation by 
signals from blood vessels. Science, 294(5542), 1–10. 
Lammert, E., Cleaver, O., & Melton, D. (2003). Role of endothelial cells in early 
pancreas and liver development. Mechanisms of Development, 120(1), 59–64.  
Lecouter, J., Kowalski, J., Foster, J., Hass, P., Zhang, Z., Dillard-Telm, L., Ferrara, N. 
(2001). Identification of an angiogenic mitogen selective for endocrine gland 
endothelium. Nature, 412(6850), 877–884.  
Lee, J. W., & Juliano, R. (2004). Mitogenic signal transduction by integrin- and growth 
factor receptor-mediated pathways. Molecules and Cells, 17(2), 188–202.  
Lim, J., & Thiery, J. P. (2012). Epithelial-mesenchymal transitions: insights from 
development. Development, 139(19), 3471–3486.  
Lyttle, B. M., Li, J., Krishnamurthy, M., Fellows, F., Wheeler, M. B., Goodyer, C. G., & 
Wang, R. (2008). Transcription factor expression in the developing human fetal 
endocrine pancreas. Diabetologia, 51(7), 1169–1180.  
Magenheim, J., Ilovich, O., Lazarus, A., Klochendler, A., Ziv, O., Werman, R., Dor, Y. 
(2011). Blood vessels restrain pancreas branching, differentiation and growth. 
Development, 138(21), 4743–4752. 
78 
 
Minton, K. (2013). Cell adhesion: Integrating the integrin response. Nature Reviews 
Molecular Cell Biology, 14(7), 401. 
Nielsen, J. H., Svensson, C., Galsgaard, E. D., Møldrup, A., & Billestrup, N. (1999). Beta 
cell proliferation and growth factors. J Mol Med, 77(1), 62–6.  
Nikolova, G., Jabs, N., Konstantinova, I., Domogatskaya, A., Tryggvason, K., Sorokin, 
L., Lammert, E. (2006). The vascular basement membrane: A niche for insulin gene 
expression and β cell proliferation. Developmental Cell, 10(3), 397–405.  
Nishimura, W., Kondo, T., Salameh, T., El Khattabi, I., Dodge, R., Bonner-Weir, S., & 
Sharma, A. (2006). A switch from MafB to MafA expression accompanies differentiation 
to pancreatic β-cells. Developmental Biology, 293(2), 526–539.  
Offield, M. F., Jetton, T. L., Labosky, P. A., Ray, M., Stein, R. W., Magnuson, M. A., 
Wright, C. V. E. (1996). PDX-1 is required for pancreatic outgrowth and differentiation 
of the rostral duodenum. Development. 122, 983–995. 
Otonkoski, T., Banerjee, M., Korsgren, O., Thornell, L.-E., & Virtanen, I. (2008). Unique 
basement membrane structure of human pancreatic islets: implications for β-cell growth 
and differentiation. Diabetes, Obesity and Metabolism, 10, 119–127.  
Pan, F. C., & Wright, C. (2011). Pancreas organogenesis: From bud to plexus to gland. 
Developmental Dynamics.240, 530-565  
Parnaud, G., Hammar, E., Rouiller, D. G., Armanet, M., Halban, P. A., & Bosco, D. 
(2006). Blockade of β1 integrin-laminin-5 interaction affects spreading and insulin 
secretion of rat β-cells attached on extracellular matrix. Diabetes, 55(5), 1413–1420.  
Peart, J., Li, J., Lee, H., Riopel, M., Feng, Z.-C., Wang, R. (2017). Critical role of β1 
integrin in postnatal beta-cell function and expansion. Oncotarget, 8(38), 62939-62952.  
Pictet, R. L., Clark, W. R., Williams, R. H., & Rutter, W. J. (1972). An ultrastructural 
analysis of the developing embryonic pancreas. Developmental Biology, 29(4), 436–467.  
Pierreux, C. E., Cordi, S., Hick, A. C., Achouri, Y., Ruiz de Almodovar, C., Prévot, P. P., 
Lemaigre, F. P. (2010). Epithelial: Endothelial cross-talk regulates exocrine 
differentiation in developing pancreas. Developmental Biology, 347(1), 216–227.  
Qin, J., Vinogradova, O., & Plow, E. F. (2004). Integrin bidirectional signaling: A 
molecular view. PLoS Biology, 2(6), 726–729.  
79 
 
Reinert, R. B., Brissova, M., Shostak, A., Pan, F. C., Poffenberger, G., Cai, Q., Powers, 
A. C. (2013). Vascular endothelial growth factor-a and islet vascularization are necessary 
in developing, but not adult, pancreatic islets. Diabetes, 62(12), 4154–4164.  
Riopel, M., Krishnamurthy, M., Li, J., Liu, S., Leask, A., & Wang, R. (2011). 
Conditional β1-integrin-deficient mice display impaired pancreatic β-cell function. 
Journal of Pathology, 224(1), 45–55. 
Riopel, M. M., Li, J., Liu, S., Leask, A., & Wang, R. (2013). β1 Integrin–Extracellular 
Matrix Interactions Are Essential for Maintaining Exocrine Pancreas Architecture and 
Function. Laboratory Investigation, 93(1), 31–40.  
Riopel, M., Stuart, W., & Wang, R. (2013). Fibrin improves beta (INS-1) cell function, 
proliferation and survival through integrin αvβ3. Acta Biomaterialia, 9(9), 8140–8148.  
Ryan, E. A., Paty, B. W., Senior, P. A., Bigam, D., Alfadhli, E., Kneteman, N. M., 
Shapiro, A. M. J. (2005). Five-year follow-up after clinical islet transplantation. Diabetes, 
54(7), 2060–2069. 
Sabek, O., Gaber, M. W., Wilson, C. M., Zawaski, J. A., Fraga, D. W., & Gaber, O. 
(2010). Imaging of human islet vascularization using a dorsal window model. 
Transplantation Proceedings, 42(6), 2112–2114.  
Saleem, S., Li, J., Yee, S. P., Fellows, G. F., Goodyer, C. G., & Wang, R. (2009). β1 
integrin/FAK/ERK signalling pathway is essential for human fetal islet cell 
differentiation and survival. Journal of Pathology, 219(2), 182–192.  
Sander, M., Sussel, L., Conners, J., Scheel, D., Kalamaras, J., Dela Cruz, F., German, M. 
(2000). Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of 
beta-cell formation in the pancreas. Development, 127(24), 5533–5540.  
Sansbury, F. H., Flanagan, S. E., Houghton, J. A. L., Shuixian Shen, F. L., Al-Senani, A. 
M. S., Habeb, A. M., Hattersley, A. T. (2012). SLC2A2 mutations can cause neonatal 
diabetes, suggesting GLUT2 may have a role in human insulin secretion. Diabetologia, 
55(9), 2381–2385.  
Scaglia, L., Cahil, C., Finegood, D., & Bonner-Weir, S. (1997). Apoptosis Participates in 
the Remodelling of the Endocrine Pancreas. Endocrinology, 138(4), 1736–1741.  
Schaffer, A. E., Taylor, B. L., Benthuysen, J. R., Liu, J., Thorel, F., Yuan, W., Sander, M. 
(2013). Nkx6.1 Controls a Gene Regulatory Network Required for Establishing and 
Maintaining Pancreatic Beta Cell Identity. PLoS Genetics, 9(1).  
80 
 
Schwitzgebel, V. M., Scheel, D. W., Conners, J. R., Kalamaras, J., Lee, J. E., Anderson, 
D. J., German, M. S. (2000). Expression of neurogenin3 reveals an islet cell precursor 
population in the pancreas. Development, 127(16), 3533–3542. 
Seymour, P. A., & Sander, M. (2011). Historical perspective: Beginnings of the β-cell: 
Current perspectives in β-cell development. Diabetes, 60(2), 364–376.  
Shah, S. R., Esni, F., Jakub, A., Paredes, J., Lath, N., Malek, M., Gittes, G. K. (2011). 
Embryonic mouse blood flow and oxygen correlate with early pancreatic differentiation. 
Developmental Biology, 349(2), 342–349.  
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., 
Rajotte, R. V. (2000). Islet Transplantation in Seven Patients with Type 1 Diabetes 
Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen. New England 
Journal of Medicine, 343(4), 230–238. 
Shattil, S. J., Kim, C., & Ginsberg, M. H. (2010). The final steps of integrin activation: 
the end game. Nat Rev Mol Cell Biol, 27(3), 320–331.  
Shih, H. P., Panlasigui, D., Cirulli, V., & Sander, M. (2016). ECM Signaling Regulates 
Collective Cellular Dynamics to Control Pancreas Branching Morphogenesis. Cell 
Reports, 14(2), 169–179.  
Skelin, M., Rupnik, M., & Cencic, A. (2010). Pancreatic beta cell lines and their 
applications in diabetes mellitus research. Altex, 27(2), 105–113.  
Stendahl, J. C., Kaufman, D. B., & Stupp, S. I. (2009). Extracellular matrix in pancreatic 
islets: Relevance to scaffold design and transplantation. Cell Transplantation, 18(1), 1–
12.  
Stephens, L., Sutherland, A., & Klimanskaya, I. (1995). Deletion of β1 integrins in mice 
results in inner cell mass failure and peri-implantation lethality. Genes and Development, 
9, 1883–1895.  
Takada, Y., Ye, X., & Simon, S. (2007). The integrins. Genome Biology, 8(5), 215.  
Takagi, J., Petre, B. M., Walz, T., & Springer, T. A. (2002). Global conformational 
earrangements in integrin extracellular domains in outside-in and inside-out signaling. 
Cell, 110(5), 599–611. 
Tamarina, N. A., Roe, M. W., & Philipson, L. H. (2014). Characterization of mice 
expressing Ins1 gene promoter driven CreERT recombinase for conditional gene deletion 
81 
 
in pancreatic β-cells. Islets, 6, 1–9.  
Thorens, B., Wu, Y. J., Leahy, J. L., & Weir, G. C. (1992). The loss of GLUT2 
expression by glucose-unresponsive β cells of db/db mice is reversible and is induced by 
the diabetic environment. Journal of Clinical Investigation, 90(1), 77–85.  
Trinder, M., Zhou, L., Oakie, A., & Riopel, M. (2016). β-cell insulin receptor deficiency 
during in utero development induces an islet compensatory overgrowth response. 
Oncotarget, 7(29), 44927–44940.  
Ulmer, T. S., Yaspan, B., Ginsberg, M. H., & Campbell, I. D. (2001). NMR Analysis of 
Structure and Dynamics of the Cytosolic Tails of Integrin αIIbβ3 in Aqueous Solution †. 
Biochemistry, 40(25), 7498–7508.  
Van Deijnen, J. H. M., Hulstaert, C. E., Wolters, G. H. J., & Van Schilfgaarde, R. (1992). 
Significance of the peri-insular extracellular matrix for islet isolation from the pancreas 
of rat, dog, pig, and man. Cell & Tissue Research, 267(1), 139–146.  
Villasenor, A., Chong, D. C., Henkemeyer, M., & Cleaver, O. (2010). Epithelial 
dynamics of pancreatic branching morphogenesis. Development, 137(24), 4295–4305.  
Vinogradova, O., Velyvis, A., Velyviene, A., Hu, B., Haas, T. A., Plow, E. F., & Qin, J. 
(2002). A structural mechanism of integrin αIIbβ3 “inside-out” activation as regulated by 
its cytoplasmic face. Cell, 110(5), 587–597.  
Wang, R., Li, J., Lyte, K., Yashpal, N. K., Fellows, F., & Goodyer, C. G. (2005). Role for 
B1 integrin and its associated α3, α5, and α6 subunits in development of the human fetal 
pancreas. Diabetes, 54(7), 2080–2089.  
Wang, Z. C., Wheeler, M. B., & Belsham, D. D. (2014). Isolation and immortalization of 
MIP-GFP neurons from the hypothalamus. Endocrinology, 155(6), 2314–2319.  
Watada, H. (2010). Role of VEGF-A in pancreatic beta cells. Endocrine Journal, 57(3), 
185–191.  
Weljie, A. M., Hwang, P. M., & Vogel, H. J. (2002). Solution structures of the 
cytoplasmic tail complex from platelet integrin alpha IIb- and beta 3-subunits. 
Proceedings of the National Academy of Sciences of the United States of America, 99(9), 
5878–83.  
Wennerberg, K., Armulik, A., Sakai, T., Karlsson, M., Fässler, R., Schaefer, E. M., 
Johansson, S. (2000). The cytoplasmic tyrosines of integrin subunit beta1 are involved in 
82 
 
focal adhesion kinase activation. Molecular and Cellular Biology, 20(15), 5758–65.  
Wicksteed, B., Brissova, M., Yan, W., Opland, D. M., Plank, J. L., Reinert, R. B., 
Dempsey, P. J. (2010). Conditional gene targeting in mouse pancreatic β-cells: Analysis 
of ectopic cre transgene expression in the brain. Diabetes, 59(12), 3090–3098.  
Xia, H., Nho, R. S., Kahm, J., Kleidon, J., & Henke, C. A. (2004). Focal adhesion kinase 
is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in 
response to contraction of type I collagen matrices via a β1 integrin viability signaling 
pathway. Journal of Biological Chemistry, 279(31), 33024–33034.  
Yang, Y., Thorel, F., Boyer, D. F., Herrera, P. L., & Wright, C. V. E. (2011). Context-
specific α -to- β -cell reprogramming by forced Pdx1 expression service re programming 
by forced Pdx1 expression. Genes and Development, (25), 1680–1685.  
Yashpal, N. K., Li, J., Wheeler, M. B., & Wang, R. (2005). Expression of β1 integrin 
receptors during rat pancreas development-sites and dynamics. Endocrinology, 146(4), 
1798–807.  
Yeh, Y. C., Wei, W. C., Wang, Y. K., Lin, S. C., Sung, J. M., & Tang, M. J. (2010). 
Transforming growth factor-β1 induces Smad3-dependent β1integrin gene expression in 
epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. American 
Journal of Pathology, 177(4), 1743–1754. 
Zhou, Q., Law, A. C., Rajagopal, J., Anderson, W. J., Gray, P. A., & Melton, D. A. 
(2007). A Multipotent Progenitor Domain Guides Pancreatic Organogenesis. 
Developmental Cell, 13, 103–114.  
Zorn, A. M., & Wells, J. M. (2009). Vertebrate Endoderm Development and Organ 
Formation. Annual Review of Cell and Developmental Biology, 25(1), 221–251.  
 
83 
 
Appendices 
Appendix A: Biosafety Approval Form 
 
 
 
84 
 
Appendix B: Animal Use Protocol 
 
 
85 
 
Curriculum Vitae 
 
Name:		 Phyo	Wei	Win	
	
Post-secondary		 University	of	Western	Ontario	
Education	and		 London,	Ontario,	Canada	
Degrees:		 	 2016	–	present,	MSc.	
	
Carleton	University		
Ottawa,	Ontario,	Canada	
2010	–	2014,	BSc.	
	
Related	Work			 Teaching	Assistant	
Experience		 	 The	University	of	Western	Ontario	
2016-2018	
	
	
